nmi_10q.htm

0001354488-14-006148.txt : 20141212 0001354488-14-006148.hdr.sgml : 20141212 20141211173624 ACCESSION NUMBER: 0001354488-14-006148 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20130930 FILED AS OF DATE: 20141212 DATE AS OF CHANGE: 20141211 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NMI Health, Inc. CENTRAL INDEX KEY: 0001088213 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 870561647 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-27421 FILM NUMBER: 141281681 BUSINESS ADDRESS: STREET 1: 50 WEST LIBERTY STREET, SUITE 880 CITY: RENO STATE: NV ZIP: 89501 BUSINESS PHONE: 914-760-7857 MAIL ADDRESS: STREET 1: 50 WEST LIBERTY STREET, SUITE 880 CITY: RENO STATE: NV ZIP: 89501 FORMER COMPANY: FORMER CONFORMED NAME: Nano Mask, Inc. DATE OF NAME CHANGE: 20090515 FORMER COMPANY: FORMER CONFORMED NAME: EMERGENCY FILTRATION PRODUCTS INC/ NV DATE OF NAME CHANGE: 19990608 10-Q 1 nmi_10q.htm QUARTERLY REPORT nmi_10q.htm

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

FORM 10-Q

þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended: September 30, 2013

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Transition Period From ________ to_________

Commission File No. 000-27421

NMI HEALTH, INC.

(Formerly, Nano Mask, Inc.)

(Exact Name of Small Business Issuer as Specified in its Charter)

NEVADA	87-0561647
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

50 West Liberty Street, Suite 880, Reno, NV	89501
(Address of principal executive offices)	(Zip code)

Issuer's telephone number, including area code: (914) 760-7857

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. (1) Yes o No þ (2) Yes þ No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ¨ No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ¨ Accelerated filer ¨ Non-accelerated filer ¨ Smaller reporting company þ

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No þ

State the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date:

At December 10, 2014, there were outstanding 20,007,170 shares of the Registrant's Common Stock, $.001 par value.

PART I

FINANCIAL INFORMATION

Table of Contents

		Page

Part I Financial Information

Item 1. Financial Statements

Balance Sheets (Unaudited) as of September 30, 2013 and December 31, 2012		3

Statements of Operations (Unaudited) for the three and nine months ended September 30, 2013 and 2012		4

Statements of Cash Flows (Unaudited) for the nine months ended September 30, 2013 and 2012		5

Notes to the Financial Statements (Unaudited)		6

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations		8

Item 3. Quantitative and Qualitative Disclosures About Market Risk		10

Item 4. Controls and Procedures		10

Part II Other Information

Item 1. Legal Proceedings		11

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		11

Item 3. Defaults by the Company on its Senior Securities		11

Item 4. Mine Safety Disclosures		11

Item 5. Other Information		11

Item 6. Exhibits		11

Signatures		12

NMI HEALTH, INC.

(Formerly, Nano Mask, Inc.)

Balance Sheets

(Unaudited)

	September 30,			December 31,
	2013			2012
ASSETS
CURRENT ASSETS
Cash	$	-		$	9,409
Accounts receivable		28,900			-
Other receivable		7,553			-
Prepaid expenses and other assets		30,000			-
Inventory, net		41,554			42,165

Total current assets		108,007			51,574
FIXED ASSETS
Equipment		933			973
Accumulated depreciation		(40	)		(519	)
		893			454
OTHER ASSETS
Non-performing assets		4,230			4,230

Total assets	$	113,130		$	56,258

LIABILITIES AND STOCKHOLDERS' DEFICIT
CURRENT LIABILITIES
Customer advances	$	21,047		$	12,545
Accounts payable		205,300			449,331
Accounts payable – related party		-			10,380
Advances from related party		423,249			207,200
Accrued expenses		686,799			687,336
Notes payable		696,226			521,157
Note payable – related party		30,000			25,000
Total current liabilities		2,062,621			1,912,949

Total liabilities		2,062,621			1,912,949

STOCKHOLDERS' DEFICIT
Common stock, $.001 par value, 100,000,000 shares authorized; 10,465,619 and 9,869,710 shares
outstanding, respectively		10,466			9,870
Additional paid-in capital		21,874,495			21,713,090
Accumulated deficit		(23,834,452	)		(23,579,651	)
Total stockholders’ deficit		(1,949,491	)		(1,856,691	)

Total liabilities and stockholders’ deficit	$	113,130		$	56,258

The accompanying notes are an integral part of these unaudited financial statements.

NMI HEALTH, INC.

(Formerly, Nano Mask, Inc.)

Statements of Operations

(Unaudited)

	For the Three Months Ended						For the Nine Months Ended
	September 30,						September 30,
	2013			2012			2013			2012

NET SALES	$	59,772		$	154,775		$	232,291		$	454,513

COSTS AND EXPENSES
Cost of sales		18,582			122,970			158,023			326,346
Research and development		16,268			-			16,268			115
Selling, general and administrative		90,918			174,158			538,361			541,988
		125,768			297,128			712,652			868,449

LOSS FROM OPERATIONS		(65,996	)		(142,353	)		(480,361	)		(413,936	)

OTHER INCOME (EXPENSE)
Gain on settlement of vendor liabilities and other		97,957			125			270,181			7,490
Loss on settlement of debt		(10.604	)		-			(10,604	)		-
Interest expense		(11,969	)		(10,773	)		(34,017	)		(31,977	)
		75,384			(10,648	)		225,560			(24,487	)

NET INCOME (LOSS)	$	9,388		$	(153,001	)	$	(254,801	)	$	(438,423	)
BASIC AND DILUTED LOSS PER SHARE	$	0.00		$	(0.02	)	$	(0.03	)	$	(0.05	)

WEIGHTED-AVERAGE NUMBER OF COMMON SHARES OUTSTANDING		10,415,337			8,841,768			10,053,584			8,638,740

The accompanying notes are an integral part of these unaudited financial statements.

NMI HEALTH, INC.

(Formerly, Nano Mask, Inc.)

Statements of Cash Flows

For the Nine Months Ended September 30, 2013 and September 30, 2012

(Unaudited)

	2013			2012
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(254,801	)	$	(438,423	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		152			498
Provision for inventory obsolescence		-			7,609
Loss on disposition of equipment		341			-
Common stock issued for company expenses incurred		123,000			161,650
Loss on settlement of debt		10,604			-
Gain on settlement of vendor liabilities and notes payable		(243,207	)		(7,490	)
Changes in operating assets and liabilities:
Accounts receivable		(28,900	)		422
Other receivable		(7,553	)		-
Prepaid expenses and other		(30,000	)		14,543
Inventory		611			(14,448	)
Customer advances		8,502			(137,972	)
Accounts payable		(10,324	)		29,194
Accrued expenses		193,479			224.195
Net cash used in operating activities		(238,096	)		(160,222	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of equipment		(933	)		-
Net cash used in investing activities		(933	)		-

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from the issuance of common shares		-			25,000
Proceeds from advances of related parties		210,000			104,460
Repayment of advances from related party		(10,380	)		(24,730	)
Proceeds from the issuance of short-term note payable		30,000			5,149
Repayments of short-term note payable		-			(1,692	)
Net cash provided by financing activities		229,620			108,187

NET INCREASE (DECREASE) IN CASH		(9,409	)		(52,035	)
CASH AT BEGINNING OF PERIOD		9,409			61,504

CASH AT END OF PERIOD	$	-		$	9,469

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for interest	$	-		$	-
Cash paid for income taxes	$	-		$	-

NON-CASH INVESTING AND FINANCING ACTIVITIES
Reduction of note payable due to a reduction in prepaid insurance	$	-		$	3,457
Common stock issued for settlement of notes payable and accrued expenses	$	28,396		$	8,703

The accompanying notes are an integral part of these unaudited financial statements.

NOTE 1 - BASIS OF PRESENTATION

The financial information included herein is unaudited and has been prepared consistent with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 8, Rule 8.03 of Regulation S-K. Accordingly, these financial statements do not include all information required by generally accepted accounting principles for annual financial statements. These statements should be read in conjunction with the audited financial statements and notes thereto included in the Company's annual report on Form 10-Kfor the year ended December 31, 2012, from which the balance sheet information as of that date is derived. These interim financial statements contain all adjustments necessary in the opinion of management for a fair statement of results for the interim periods presented.

The results of operations for the nine months ended September 30, 2013 are not necessarily indicative of the results to be expected for the full year.

Certain minor reclassifications in prior period amounts have been made to conform to the current period presentation.

NOTE 2 – GOING CONCERN

The Company’s financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, in addition to a working capital deficiency at September 30, 2013, the Company has incurred negative cash flow from operations and losses which have substantially increased its operating deficit at September 30, 2013. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

The Company’s ability to continue as a going concern will be dependent upon economic developments and the success of management's plans as set forth below, which cannot be assured. The accompanying financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result from the outcome of this uncertainty. Management and board members are continuing to discuss other alternative financing options, but no definitive proposals or agreements have been reached.

The foregoing notwithstanding, management does not believe the Company currently has sufficient capital to sustain its planned business activities for the next twelve months following the issuance of these financial statements. Accordingly, while management has historically been successful generating sufficient funds to sustain operations, there is no assurance that they will continue to do so. Nevertheless, the Company may seek additional capital to sustain its operations, either through equity or loans, possibly unsecured, until such time as its operations are self-sustaining. These funds will be required to continue the Company’s efforts to generate sales of its products and to provide sufficient working capital to meet the expected sales demand.

NOTE 3 –SIGNIFICANT TRANSACTIONS

In April 2013 the Company authorized a name change from Nano Mask, Inc. to NMI Health, Inc. to better reflect the nature of its products. On June 5, 2013 the Company completed a 1 for 10 reverse split of its common shares. Following the reverse split, the Company maintained 9,869,710 common shares outstanding.

In July, 2013 the Company issued 465,909 common shares to a key officer for his $123,000 in accrued payroll.

As of August 1, 2013, a Company affiliate converted a note of $25,000, plus interest of $3,396, into 130,000 common shares. The shares were issued at a fair value of $39,000 resulting in a loss on settlement of debt of $10,604. On September 22, 2013 the same shareholder loaned the Company $30,000, plus interest, at an annual rate of 10%, convertible at $0.05 per share. The note is unsecured and is due on September 22, 2015.

Repayments of advances from a related party were made in the amount of $10,380 for the nine months ended September 30, 2013.

In August, 2013 a judgment was awarded to Applied Nanoscience, Inc. against the Company in the amount of $601,041, including interest at prime rate, plus 2%, and attorney fees. The Company had already reflected a balance owed in excess of this. In September 2013, a note payable for $13,832, plus related interest, expired under applicable statutes of limitation. These two events both generated gains of $97,957 for the Company.

During the nine months ended September 30, 2013, the Company received cash advances of $210,000 from one executive officer with no specific repayment terms and another officer paid expenses on behalf of the Company in the amount of $6,049. The total balance outstanding at September 30, 2013 is $423,249.

A gain of $145,251 was generated from expiry of certain accounts payable under applicable statutes of limitations during the nine months ended September 30, 2013. Also, during the nine months ended September 30, 2013 the Company realized a gain of $26,973 from disposition of common shares in Medmarc Insurance Company which was a mutual insurance company that was bought by another company. Since the Company had maintained its insurance through Medmarc, the Company was designated a percentage of the final sales proceeds from the sale of Medmarc. $7,553 was withheld as Federal income taxes and is reflected as other receivable.

NOTE 4 – SUBSEQUENT EVENTS

Subsequent to September 30, 2013, the Company received cash advances from one executive officer of $27,200 and another officer incurred expenses of $1,658 on behalf of the Company.

On April 15, 2014 a note for $30,000 including interest of $1,696 was converted into 633,921 common shares. Further, on May 15, 2014 the same shareholder provided $20,000 at no interest as an unsecured loan.

Also on April 15, 2014, Applied Nanoscience, Inc. and the Company agreed to settle the outstanding $601,041 judgment for 500,000 restricted common shares (valued at $0.025 per share on the date of the settlement) and $175,000 payable in three instalments ending on October 15, 2014. The Company has paid $20,000 to date.

Finally, on April 15, 2014 the Company authorized the issuance of 4,610,810 common shares to Company officers and employees at a value of $0.15 per share in satisfaction of accrued payroll and director fees. And on the same date, 500,000 common shares valued at $12,500 were awarded to two individuals for services performed.

During the two months ended June 30, 2014, 75,000 shares of common stock were issued in a private placement to two individual investors for $15,000 in cash. Also, in November 2014, an additional 125,000 common shares were issued in a private placement to an individual for $25,000 in cash.

On October 9, 2014 the Company issued 2,222,000 common shares to an affiliate shareholder in settlement of his unsecured loan of $444,400. Also, on the same date officers and employees agreed to receive 874,820 common shares to settle $131,223 in accrued payroll.

Subsequent to September 30, 2013 the Company generated $38,663 in gains from expiry of certain accounts payable under applicable statutes of limitations. Also, the Company generated gains of $473,385 from settlement of various notes payable and from the expiry of certain notes under applicable statutes of limitations.

NOTE 5 – CONTINGENCIES

On March 5 2012, the Company received a complaint from a certain attorney seeking collection of his invoices in the amount of $167,167, plus interest and litigation expenses. The Company does not believe the claim has any merit and has submitted a motion for dismissal. At this point, the Company has been awaiting the claimant’s amendment to his claim. Recently, the Company decided to pursue further efforts to seek dismissal of the complaint.

On or about May 8, 2012, the Company received a complaint from a certain former employee seeking collection of his charges as a distributor and as an employee in the amount of $409,525, plus interest and litigation expenses. The Company believes the likelihood of loss in this case is remote and intends to offset for certain expenditures made by the Company caused by employee. The Company has already recognized $37,500 as a liability at September 30, 2013.

ITEM 2

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Cautionary Statement Regarding Forward-looking Statements

This report may contain "forward-looking" statements. Examples of forward-looking statements include, but are not limited to: (a) projections of revenues, capital expenditures, growth, prospects, dividends, capital structure and other financial matters; (b) statements of plans and objectives of our management or Board of Directors; (c) statements of our future economic performance; (d) statements of assumptions underlying other statements and statements about us and our business relating to the future; and (e) any statements using the words "anticipate," "expect," "may," "project," "intend" or similar expressions.

Overview

NMI Health is a healthcare product development and distribution company providing innovative and cost effective emergency and critical care and infection control products to a variety of market segments within the healthcare industry. Our customers range from hospitals, emergency services, surgery centers, long-term care facilities, nursing homes and other clinical settings throughout the healthcare continuum.

Since its inception, we have been involved in the development of its technology. Through September 30, 2013, revenues have not been adequate to cover operating expenses and thus, the Company has reported a loss in each of its years of existence. Through September 30, 2013, we have funded ourselves by way of a series of private equity placements and this has offset its accumulated deficit in this manner.

Results of Operations for the Three Months Ended September 30, 2013 compared with 2012

Revenues: During the three months ended September 30, 2013, revenues of approximately $60,000 were generated from Textiles (100%). During the three months ended September 30, 2012, there were revenues of approximately $155,000 derived from sale of Textiles (100%).

Cost of Sales: Cost of sales as a percentage of sales approximated 31% for the three months ended September 30, 2013 compared with 79% in the similar period of 2012. This lower percentage in the last three months is attributable to higher margins from our product mix in this period.

Operating Expenses: During the three months ended September 30, 2013 the Company’s general and administrative expenses decreased by approximately $83,000 or 48%, compared to the three months ended September 30, 2012, primarily due to a significant decrease in salaries and director fees ($71,000), as well as marketing and related expenses ($12,000). The significant components of our operating expenses include salaries and wages, consulting and other professional services, accounting, audit and legal fees, product and liability insurance and travel.

Research and development: Research and development (R&D) expenditures have become less meaningful in both 2013 and 2012 as management devotes its limited resources to the products that it has recently developed through third-party sources. However, the Company attempted to satisfy a customer request for airline seat covers that proved unsatisfactory to the customer specifications for which we expended $16,000 in R & D costs. If resources are available in the future, the Company intends to bring additional products to market, assuming those products are considered viable at the time the resources are available. The typical components of the Company’s research and development costs ordinarily include prototype development and materials, governmental filings and laboratory testing.

Results of Operations for the Nine Months Ended September 30, 2013 compared with 2012

Revenues: During the nine months ended September 30, 2013, revenues of approximately $232,000 were derived from Nano Masks (54%) and Textiles (46%). During the nine months ended September 30, 2012, revenues of approximately $455,000 reflect the following products: Textiles (97%) and NanoZyme products (3%).

Cost of Sales: The cost of sales percentage to sales of 68% during the nine months ended September 30, 2013 declined from the 72% for the nine months ended September 30, 2012, largely due to higher margin products sold in the period.

Operating Expenses: During the nine months ended September 30, 2013, the Company reduced general and administrative expenses by approximately $4,000 or approximately 1% compared to the nine months ended September 30, 2012, primarily attributable to reduced salaries and director fees ($74,000), lower marketing related expenses ($11,000) and lower audit fees ($26,000) offset by higher website development costs ($31,000), higher travel expenses ($27,000), higher health insurance ($14,000) and higher direct selling expenses ($35,000).

Research and development:

Research and development (R&D) expenditures have become less meaningful in both 2013 and 2012 as management devotes its limited resources to the products that it has recently developed through third-party sources. However, the Company attempted to satisfy a customer request for airline seat covers that proved unsatisfactory to the customer specifications for which we expended $16,000 in R & D costs. If resources are available in the future, the Company intends to bring additional products to market, assuming those products are considered viable at the time the resources are available. The typical components of the Company’s research and development costs ordinarily include prototype development and materials, governmental filings and laboratory testing.

Liquidity and Capital Resources

The Company has not been able to generate sufficient net cash inflows from operations to sustain its business efforts and accommodate its growth plans. During the nine months ended September 30, 2013, the Company received cash advances from one executive officer of $210,000 with no specific repayment terms. And one other officer paid expenses on behalf of the Company in the amount of $6,049.

The Company does not believe, however, that it currently has sufficient capital to sustain its business efforts for the next twelve months. Accordingly, the Company will need to raise additional capital in the near future to sustain operations.

Accordingly, for these and other reasons, there is significant uncertainty regarding the Company’s future, and the Company’s auditors expressed substantial doubt as to the Company’s ability to continue as a going concern in their report on the Company’s 2012 audited financial statements. The Company may seek capital through equity or loans until such time as its operations are self-sustaining. These funds will be required to continue the Company’s efforts to generate sales of its products and to provide sufficient working capital to meet the expected sales demand.

Impact of Inflation

At this time, the Company does not anticipate that inflation will have a material impact on its current or future operations.

Critical Accounting Policies and Estimates

Except with regard to the estimated useful lives of patents and acquired technology, the net realizable value of the Company’s inventory due to shelf-life issues and design, the allowance for bad debts on accounts receivable, and the effective provision of a 100% deferred income tax asset valuation allowance, the Company does not employ any critical accounting policies or estimates that are either selected from among available alternatives or require the exercise of significant management judgment to apply or that if changed are likely to materially affect future periods.

Management reviews the carrying value of the technology assets annually based on its current marketing activities, plans and expectations, and the perceived effects of competitive factors and possible obsolescence, whether any write-downs should be taken or whether the estimated useful lives should be shortened.

Management also reviews the carrying value of its inventory periodically for evidence of declines in estimated fair value and considers, based on its current marketing activities, plans and expectations, and the perceived effects of competitive factors and possible obsolescence due to shelf-life issues on the environmental filters, whether any write-downs should be taken.

Management also reviews the collectability of outstanding receivables based upon historical collection history from each customer, the age of the receivables, and the customers wherewithal to pay the outstanding balance, and records an estimated allowance for bad debts sufficient to cover any potential losses to be incurred for non-collections.

The carrying values of prepaid expenses, accounts payable, accrued expenses and short term notes payable generally approximate the respective fair values of these instruments due to their current nature.

Recent Accounting Pronouncements

While there have been Financial Accounting Standards Board (FASB) pronouncements made effective subsequent to the issuance of these financial statements, none would have required restatement of the financial statements herein nor have they had any significant effect on future financial statements of the Company.

ITEM 3

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Smaller reporting companies are not required to provide the information required by this item.

ITEM 4

CONTROLS AND PROCEDURES

We maintain a system of disclosure controls and procedures that are designed for the purpose of ensuring that information required to be disclosed in our SEC reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the Company’s management, including the Chief Executive Officer and the Principal Accounting Officer, as appropriate to allow timely decisions regarding required disclosures.

Evaluation of Disclosure Controls and Procedures

As required by Rule 13a-15 under the Securities Exchange Act of 1934, as of the end of the period covered by this quarterly report, being September 30, 2013, we have carried out an evaluation of the effectiveness of the design and operation of our company’s disclosure controls and procedures. This evaluation was carried out under the supervision and with the participation of our company’s management, including our company’s Chief Executive Officer and Chief Financial Officer. Based upon that evaluation, our company’s Chief Executive Officer and Chief Financial Officer concluded that our company’s disclosure controls and procedures are ineffective as at the end of the period covered by this report. There have been no changes in our internal controls over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect our internal controls over financial reporting.

Disclosure controls and procedures and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time period specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934 is accumulated and communicated to management including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

PART II

OTHER INFORMATION

ITEM 1 - LEGAL PROCEEDINGS

On March 5 2012, the Company received a complaint from a certain attorney seeking collection of his invoices in the amount of $167,167, plus interest and litigation expenses. The Company does not believe the claim has any merit and has submitted a motion for dismissal. At this point, the Company is awaiting the claimant’s amendment to his claim. Recently, the Company decided to pursue further efforts to seek dismissal of the complaint.

ITEM 2 - UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

During two months ended June 30, 2014, 75,000 shares of common stock were issued in a private placement to two individual investors for $15,000 in cash. In November 2014, an additional 125,000 common shares were issued in a private placement from an individual for $25,000 in cash.

These shares were issued in reliance on the exemption from registration and prospectus delivery requirements of the Act set forth in Section 3(b) and/or Section 4(2) of the Securities Act and the regulations promulgated hereunder.

ITEM 3 - DEFAULTS BY THE COMPANY ON ITS SENIOR SECURITIES

None.

ITEM 4 - MINE SAFETY DISCLOSURES

N/A

ITEM 5 - OTHER INFORMATION

None.

ITEM 6 - EXHIBITS

EXHIBIT NO.		DESCRIPTION

31		CERTIFICATION OF PRINCIPAL EXECUTIVE AND FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002.
31		CERTIFICATION OF PRINCIPAL EXECUTIVE AND FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002.
32		CERTIFICATION OF PRINCIPAL EXECUTIVE AND FINANCIAL OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002.
32		CERTIFICATION OF PRINCIPAL EXECUTIVE AND FINANCIAL OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002.
101.INS		XBRL INSTANCE DOCUMENT
101.SCH		XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
101.CAL		XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
101.DEF		XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
101.LAB		XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
101.PRE		XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT

SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NMI HEALTH, INC.
	(Formerly, Nano Mask, Inc.)

December 10, 2014	By:	/s/Edward Suydam
		Edward Suydam, Chief Executive Officer


December 10, 2014		/s/Michael J. Marx
		Michael J. Marx, Chief Financial Officer

EX-31.1 2 nmi_ex311.htm CERTIFICATION nmi_ex311.htm

Exhibit 31.1

CERTIFICATION PURSUANT TO RULE 13a-14

UNDER THE SECURITIES EXCHANGE ACT OF 1934

I, Edward Suydam, certify that:

(1) I have reviewed this quarterly report on Form 10-Q of Nano Mask, Inc. for the quarter ended September 30, 2013;

(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4) The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Dsigned such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;

(5) The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions);

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	Nano Mask, Inc.

Date December 10, 2014	By:	/s/ Edward Suydam
		Name Edward Suydam
		Title Chief Executive Officer (Principal Executive Officer)

EX-31.2 3 nmi_ex312.htm CERTIFICATION nmi_ex312.htm

Exhibit 31.2

CERTIFICATION PURSUANT TO RULE 13a-14

UNDER THE SECURITIES EXCHANGE ACT OF 1934

I, Michael J. Marx, certify that:

(1) I have reviewed this quarterly report on Form 10-Q of Nano Mask, Inc. for the quarter ended September 30, 2013;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	Nano Mask, Inc.

Date December 10, 2013	By:	/s/ Michael J. Marx
		Name Michael J. Marx
		Title Chief Financial Officer (Principal Accounting Officer)

EX-32.1 4 nmi_ex321.htm CERTIFICATION nmi_ex321.htm

Exhibit 32.1

Certification Pursuant to Section 1350 of Chapter 63

of Title 18 of the United States Code

I, Edward Suydam, the Chief Executive Officer of Nano Mask, Inc. (“Nano Mask”), certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

(i) the accompanying Form 10-Q of Nano Mask for the quarter ended September 30, 2013 (the “Form 10-Q”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(ii) the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Nano Mask, Inc.

	Nano Mask, Inc.

Date December 10, 2013	By:	/s/ Edward Suydam
		Name Edward Suydam
		Title Chief Executive Officer (Principal Executive Officer)

EX-32.2 5 nmi_ex322.htm CERTIFICATION nmi_ex322.htm

Exhibit 32.2

Certification Pursuant to Section 1350 of Chapter 63

of Title 18 of the United States Code

I, Michael J. Marx, the Chief Financial Officer of Nano Mask, Inc. (“Nano Mask”), certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

(ii) the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Nano Mask, Inc.

	Nano Mask, Inc.

Date December 10, 2013	By:	/s/ Michael J. Marx
		Name Michael J. Marx
		Title Chief Financial Officer (Principal Accounting Officer)

EX-101.INS 6 nanm-20130930.xml 0001088213 2013-01-01 2013-09-30 0001088213 2013-09-30 0001088213 2012-12-31 0001088213 2012-07-01 2012-09-30 0001088213 2012-01-01 2012-09-30 0001088213 2011-12-31 0001088213 2012-09-30 0001088213 2013-07-01 2013-09-30 0001088213 2014-12-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares NMI Health, Inc. 0001088213 10-Q 2013-09-30 false --12-31 No No No Smaller Reporting Company 2013 Q3

893

454

519

933

973

108007

51574

41554

42165

30000

28900

113130

56258

4230

113130

56258

-1949491

-1856691

-23834452

-23579651

21874495

21624265

10466

98695

2062621

1912949

2062621

1912949

30000

25000

696226

521157

686799

687336

10380

205300

449331

21047

12545

.001

100000000

10465619

9869710

7553

423249 207200

9409

61504

9469

The financial information included herein is unaudited and has been prepared consistent with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 8, Rule 8.03 of Regulation S-K. Accordingly, these financial statements do not include all information required by generally accepted accounting principles for annual financial statements. These statements should be read in conjunction with the audited financial statements and notes thereto included in the Company's annual report on Form 10-Kfor the year ended December 31, 2012, from which the balance sheet information as of that date is derived. These interim financial statements contain all adjustments necessary in the opinion of management for a fair statement of results for the interim periods presented.   The results of operations for the nine months ended September 30, 2013 are not necessarily indicative of the results to be expected for the full year.   Certain minor reclassifications in prior period amounts have been made to conform to the current period presentation.

The Companys financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, in addition to a working capital deficiency at September 30, 2013, the Company has incurred negative cash flow from operations and losses which have substantially increased its operating deficit at September 30, 2013. These factors raise substantial doubt about the Companys ability to continue as a going concern.   The Companys ability to continue as a going concern will be dependent upon economic developments and the success of management's plans as set forth below, which cannot be assured. The accompanying financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result from the outcome of this uncertainty.  Management and board members are continuing to discuss other alternative financing options, but no definitive proposals or agreements have been reached.   The foregoing notwithstanding, management does not believe the Company currently has sufficient capital to sustain its planned business activities for the next twelve months following the issuance of these financial statements. Accordingly, while management has historically been successful generating sufficient funds to sustain operations, there is no assurance that they will continue to do so. Nevertheless, the Company may seek additional capital to sustain its operations, either through equity or loans, possibly unsecured, until such time as its operations are self-sustaining.  These funds will be required to continue the Companys efforts to generate sales of its products and to provide sufficient working capital to meet the expected sales demand.

In April 2013 the Company authorized a name change from Nano Mask, Inc. to NMI Health, Inc. to better reflect the nature of its products.  On June 5, 2013 the Company completed a 1 for 10 reverse split of its common shares.  Following the reverse split, the Company maintained 9,869,710 common shares outstanding.   In July, 2013 the Company issued 465,909 common shares to a key officer for his $123,000 in accrued payroll.   As of August 1, 2013, a Company affiliate converted a note of $25,000, plus interest of $3,396, into 130,000 common shares. The shares were issued at a fair value of $39,000 resulting in a loss on settlement of debt of $10,604. On September 22, 2013 the same shareholder loaned the Company $30,000, plus interest, at an annual rate of 10%, convertible at $0.05 per share. The note is unsecured and is due on September 22, 2015.   Repayments of advances from a related party were made in the amount of $10,380 for the nine months ended September 30, 2013.   In August, 2013 a judgment was awarded to Applied Nanoscience, Inc. against the Company in the amount of $601,041, including interest at prime rate, plus 2%, and attorney fees. The Company had already reflected a balance owed in excess of this. In September 2013, a note payable for $13,832, plus related interest, expired under applicable statutes of limitation. These two events both generated gains of $97,957 for the Company.   During the nine months ended September 30, 2013, the Company received cash advances of $210,000 from one executive officer with no specific repayment terms and another officer paid expenses on behalf of the Company in the amount of $6,049. The total balance outstanding at September 30, 2013 is $423,249.   A gain of $145,251 was generated from expiry of certain accounts payable under applicable statutes of limitations during the nine months ended September 30, 2013. Also, during the nine months ended September 30, 2013 the Company realized a gain of $26,973 from disposition of common shares in Medmarc Insurance Company which was a mutual insurance company that was bought by another company. Since the Company had maintained its insurance through Medmarc, the Company was designated a percentage of the final sales proceeds from the sale of Medmarc. $7,553 was withheld as Federal income taxes and is reflected as other receivable.

Subsequent to September 30, 2013, the Company received cash advances from one executive officer of $27,200 and another officer incurred expenses of $1,658 on behalf of the Company.   On April 15, 2014 a note for $30,000 including interest of $1,696 was converted into 633,921 common shares. Further, on May 15, 2014 the same shareholder provided $20,000 at no interest as an unsecured loan.   Also on April 15, 2014, Applied Nanoscience, Inc. and the Company agreed to settle the outstanding $601,041 judgment for 500,000 restricted common shares (valued at $0.025 per share on the date of the settlement) and $175,000 payable in three instalments ending on October 15, 2014. The Company has paid $20,000 to date.   Finally, on April 15, 2014 the Company authorized the issuance of 4,610,810 common shares to Company officers and employees at a value of $0.15 per share in satisfaction of accrued payroll and director fees. And on the same date, 500,000 common shares valued at $12,500 were awarded to two individuals for services performed.   During the two months ended June 30, 2014, 75,000 shares of common stock were issued in a private placement to two individual investors for $15,000 in cash. Also, in November 2014, an additional 125,000 common shares were issued in a private placement to an individual for $25,000 in cash.   On October 9, 2014 the Company issued 2,222,000 common shares to an affiliate shareholder in settlement of his unsecured loan of $444,400. Also, on the same date officers and employees agreed to receive 874,820 common shares to settle $131,223 in accrued payroll.   Subsequent to September 30, 2013 the Company generated $25,025 in gains from expiry of certain accounts payable under applicable statutes of limitations. Also, the Company generated gains of $487,137 from settlement of various notes payable and from the expiry of certain notes under applicable statutes of limitations.

On March 5 2012, the Company received a complaint from a certain attorney seeking collection of his invoices in the amount of $167,167, plus interest and litigation expenses. The Company does not believe the claim has any merit and has submitted a motion for dismissal. At this point, the Company has been awaiting the claimants amendment to his claim. Recently, the Company decided to pursue further efforts to seek dismissal of the complaint.   On or about May 8, 2012, the Company received a complaint from a certain former employee seeking collection of his charges as a distributor and as an employee in the amount of $409,525, plus interest and litigation expenses. The Company believes the likelihood of loss in this case is remote and intends to offset for certain expenditures made by the Company caused by employee. The Company has already recognized $37,500 as a liability at September 30, 2013.

145251 27200 20007170

10053584

8841768

8638740

10415337

-0.03

-0.02

-0.05

270181

125

7490

97957

-480361

-142353

-413936

-65996

712652

297128

868449

125768

538361

174158

541988

90918

16268

115

16268

158023

122970

326346

18582

232291

154775

454513

59772

34017

10773

31977

11969

225560

-10648

-24487

75384

-254801

-153001

-438423

9388

28396

8703

-9409

-52035

229620

108187

1692

30000

5149

210000

104460

25000

-238096

-160222

193479

224195

-10324

29194

8502

-137972

611

-14448

-30000

14543

-7553 0

-28900

422

-243207 -7490

123000

161650

152

498

933

-933

10380

24730

0 3457

7609

341

10604 0

-10604

EX-101.SCH 7 nanm-20130930.xsd 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - 1. Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - 2. Going Concern link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - 3. Significant Transactions link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - 4. Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - 5. Contingencies link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - 3. Significant Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - 4. Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 nanm-20130930_cal.xml EX-101.DEF 9 nanm-20130930_def.xml EX-101.LAB 10 nanm-20130930_lab.xml Settlement of Liabilities Class of Stock [Axis] Settlement Of Advances Related Party Compensation Cash Proceeds Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] CURRENT ASSETS Cash Accounts receivable Other receivable Prepaid expenses Inventory, net Total current assets FIXED ASSETS Equipment and molds Accumulated depreciation Net fixed assets OTHER ASSETS Non-performing assets Total assets LIABILITIES AND STOCKHOLDERS' DEFICIT Current Liabilities Customer advances Accounts payable Acounts payable - related party Advances from related party Accrued expenses Notes payable Note payable - related party Total current liabilities Total liabilities STOCKHOLDERS' DEFICIT Common stock, $.001 par value, 100,000,000 shares authorized; 10,465,619 and 9,869,710 shares outstanding, respectively Additional paid-in capital Accumulated deficit Total stockholders' deficit Total liabilities and stockholders' deficit Common stock, par value Common stock, authorized shares Common stock, outstanding shares Income Statement [Abstract] NET SALES COSTS AND EXPENSES Cost of goods sold Research and development Selling, general and administrative Total expenses LOSS FROM OPERATIONS OTHER INCOME (EXPENSE) Gain on settlement of vendor liabilities and other Loss on settlement of debt Interest expense Total other income (expense) NET INCOME (LOSS) BASIC AND FULLY-DILUTED INCOME (LOSS) PER SHARE WEIGHTED-AVERAGE NUMBER OF COMMON SHARES OUTSTANDING Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net loss Adjustments to reconcile net loss to net cash used in operating activities: Depreciation Provision for inventory obsolescence Loss on disposition of equipment Common stock issued for services Loss on settlement of debt Gain on settlement of vendor liabilities Changes in operating assets and liabilities: Accounts receivable Other receivable Prepaid expenses and other Inventory Customer advances Accounts payable Accrued expenses Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of equipment Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from issuance of common shares Proceeds from advances of related parties Repayment of advances from related party Proceeds from issuance of short-term note payable Repayments of short-term note payable Net cash provided by financing activities NET INCREASE (DECREASE) IN CASH CASH AT BEGINNNING OF PERIOD CASH AT END OF PERIOD SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Cash paid for interest Cash paid for income taxes NON-CASH INVESTING AND FINANCING ACTIVITIES Reduction of note payable due to a reduction in prepaid insurance Common stock issued for settlement of notes payable and accrued expenses Accounting Policies [Abstract] 1. Basis of Presentation Text Block [Abstract] 2. Going Concern Supplemental Cash Flow Elements [Abstract] 3. Significant Transactions Subsequent Events [Abstract] 4. Subsequent Events Commitments and Contingencies Disclosure [Abstract] 5. Contingencies Significant Transactions Details Narrative Repayments of advances from related party Gain genereated by writing off payables Cash advances from executive officers Assets, Current Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property, Plant and Equipment, Net Assets Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Interest Expense Nonoperating Income (Expense) LossOnSettlementOfDebt Increase (Decrease) in Accounts Receivable OtherReceivable Increase (Decrease) in Customer Advances Increase (Decrease) in Accounts Payable Increase (Decrease) in Accrued Liabilities Net Cash Provided by (Used in) Operating Activities Payments to Acquire Machinery and Equipment Net Cash Provided by (Used in) Investing Activities Repayments of Notes Payable Net Cash Provided by (Used in) Financing Activities Cash, Period Increase (Decrease) EX-101.PRE 11 nanm-20130930_pre.xml EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0`8$;S/C@$``&L*```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,EEU/PC`4AN]-_`]+;PWK MAHIH&%SX<:DDX@^HZQE;Z-JF+0C_WK/R$4,FA$AB;]:L[7G?9V=)^PY&RUI$ M"S"V4C(C:9R0"&2N>"6G&?F8O'3Z)+*.2#"8K#3;":FDS M4CJG'RBU>0DUL['2('&E4*9F#E_-E&J6S]@4:#=)>C17TH%T'==HD.'@"0HV M%RYZ7N+TFL2`L"1Z7&]LO#+"M!95SAR2TH7D>RZ=C4.,E7Z/+2MMKQ"#T%:' M9N5W@TW=&[;&5!RB,3/NE=6(09>"?BDS^U1J%A\6::%415'EP%4^K[$#L=4& M&+X9I7<)4#]<^_]\++'+E+K%L)L&?^_VO18\XE M,\#?G<'0"##31C0-O\:8^*@Z_`0``__\#`%!+`P04``8`"````"$`M54P(_4```!, M`@``"P`(`E]R96QS+RYR96QS(*($`BB@``(````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M`````````````````````````````````````````````````````````(R2 MST[#,`S&[TB\0^3[ZFY("*&ENTQ(NR%4'L`D[A^UC:,D0/?VA`."2F/;T?;G MSS];WN[F:50?'&(O3L.Z*$&Q,V)[UVIXK9]6#Z!B(F=I%,<:CAQA5]W>;%]X MI)2;8M?[J+*+BQJZE/PC8C0=3Q0+\>QRI9$P4P>J/OH\^;*W-$UO>"_F?6*73HQ`GA,[RW;E0V8+J<_;J)I"RTF# M%?.J,Y@2@$``-((```: M``@!>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;',@H@0!**```0`````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````"\UDMN@S`0!N!]I=X!>=\8DW<5DDU5 M*=LV/8`%$T`!&WG<1V[?$4JAD=+I!GF#9%O,?/X%F,WNJZFC#W!869,*-8E% M!":S>66*5+P=GA]6(D*O3:YK:R`59T"QV][?;5Z@UIYNPK)J,:(J!E-1>M\^ M2HE9"8W&B6W!T,K1ND9[&KI"MCH[Z0)D$L<+Z7[7$-NKFM$^3X7;Y]3_<&ZI M\_^U[?%89?!DL_<&C+_10GY:=\(2P%-1[0KPJ>BG4'8KJPF)A;R-4=,Q-9Y2 M@D'2#65W51QB5$.__<'13UT2F7*8Y9B!])W_QBPYC$H":U3"<4)K6(P*'0V7 MS"(P9L%A5/!HV-=['CB;.9O-J!HLM8/\U3LZ79"V>?D$7TVS&CJ=@AX&*N8X ML\":&8=9!\:L.8P:-1KTYYI^.X;GI1O_])=7?R+;;P```/__`P!02P,$%``& M``@````A`'ALP)?B0Q;`=PXK3>I`;L)$MB(HTL(A*IDE3L_'U&5.W2:HMV)?$Q MEV?N##F].51E\(;:""5G++Z(6(`R59F0NQE[W-Y_N6*!L2`S*)7$&7M'PV[F MGS]-]TJ_OBCU&I"`-#-66%M/PM"D!59@+E2-DE9RI2NP--2[T-0:(3,%HJW* M,(FB<5B!D*Q3F.C_T5!Y+E*\4VE3H;2=B,82+.&;0M2&S:>Y*/&IRRB`NGZ` MBK@/)0M*,':9"8O9C(UHJ/9X-J&;>M&(DE:O!]&`A?-3DFL=9)A#4]HMI7=4 M)[^289*,VYVM%4\"]^974#L,#L]"9FK?;B5KWT^C`0'LW=*SR&Q!ZU$4G>:^ MH=@5]CA)\J&G[QRD<]PWD"Z]HR.<*L67T@K[SE>R?/*/^#5H*E*!5J1`]I\8!IZ&L]EG MV%BP9+&D\U7.O]>HN^)V-)[*T%,9]DG.56[!%/R>ZOTS)T^%+#_Y,>JKQ'P! M1CB0M49#4([%"X_]7%PC^+DD_*NBB\1O%;FJJ=-/%L0^_67_W`'?B)T4U.H@ M+=]JD`92U^*^A(]^U9<8\DWS8O!'0]!\^=;ZZ<>.O;2O^[&C%M@2.+T$@NZ[ MAWWIQ<51/_#OW/P.K:]SUH:_]>$?X%L!$*7A#^#K^.T8NWX,G<=T/:CG4KJW M[:=M?`<;'E^M^0<```#__P,`4$L#!!0`!@`(````(0!-6N.+,P4``"@3```8 M````>&PO=V]R:W-H965T&ULE)C?;Z,X$,??3[K_`?&>@`'S M(TJR*H'>K;0GG4ZW>\^4.`EJP!'0IOWO;XP)V$.;I"^[#7P\GN_,V!Z\_/96 M'HU75C<%KU8FF=NFP:J<;XMJOS)__OLX"TVC:;-JFQUYQ5;F.VO,;^O??UN> M>?W<'!AK#;!0-2OST+:GA64U^8&563/G)U;!FQVORZR%G_7>:DXUR[;=H/)H M.;;M6V565*:TL*COL<%WNR)G"<]?2E:UTDC-CED+_C>'XM1;*K'Y^ M.0U;_BNG8,Y M2SHZU1Q9D066ULMM`0I$V(V:[5;F`UFD)#2M];(+T*^"G1OE;Z,Y\/,?=;'] M450,H@UY$AEXXOQ9H-^WXA$,MB:C'[L,_%T;6[;+7H[M/_S\)ROVAQ;234&1 M$+;8OB>LR2&B8&;N4&$IYT=P`/XURD*4!D0D>^O^/Q?;]K`R77].`]LE@!M/ MK&D?"V'2-/*7IN7E?Q(BO2EIQ.F-P(C>"''F3D@)]6];L:1'G<`D:[/ULN9G M`ZH&YFQ.F:A!L@#+%V72CT'K9U)!HS#R(*RLS,`T0$4#^7E=^][2>H60YCT2 M?X!0'=E<$!%`83:Y/!C-$GU(>B%$]D#1(`N"IY7Y`@8*DSQW@]TWV*)>`J".W)\M`:],B-V0'#]$\B02=H5(HR!`@=^H[PGU@@"I3U3`<1TGPG6G`A[U M*'$'%S1EL*3N5R9@E+AH,-NMB%@B,/L@'KF^N4DD-XGT&J')\[\B3\!ZX@(; MR9.(WR6.A#3$B=/>0UJP@40#:&@[8UZZ`*8JX#J^ZXW+5E,&>]G]B1,P4H8* M)I9(K\QW<,ENY'NO4XZBDMP8FZIC"1D+0A,D>A%EH[^^(PH8"4*IB"4B!45V M1-`:W*CO2>`1BH!$!:@;NCX*6:H!'HG"T8*F+/J*,@$C9:A$8HGTJ7)H,,F5 M"D`-$F=T3)Y;*@"O?8J"EZI`Z(>>-ZYS31J!5N7^K'4T$C,"Z)S?]%9Z@GB.2U&$$AWQ0GN:/(00-W+'B72-X@R_NS*)//'A:!EV0+Q[ MQSUS;9>\C22WD?0JHHL49[TB4O19+J3B^C(DLD-0S[I@C*(\$7JF7XA!1-%9 MO^D!N;5`PZEON8DVW@EL$N)UJ!&!%XW;DRY1'/>*Q!O29'.@24.>QT0RETJT M?1M5\Z8G/MXV;PY//QFNRQ)'_?VR9&.@R4*[0TPD*D^BTN@#1HRKPL4I_W]`F5OH`E$[L?BTVC88P+8VR=I4X$9L7T/ MQ2C13#@.I?Y8=5V,4HV8.9X7?J9/'/GWZY,-@JHO1%/'1#*ROXQ^ MGQ'JVC9:4XEF8N90V$,1DNJ(!U%4FAD]@Z(!4!3>N;G(MD%3BGR(B62D4A2& M3?\RZGJ6F3VWT2F73`!4Q>D$&##A&UL[%E/;]LV%+\/V'<@=&]M)[8;!W6*V+&;K4T;Q&Z''FF9 MEEA3HD#227T;VN.``<.Z89UC1"SF67"72(6=L#/F-^-"0/E(<8E@HFVE[5_+S*UM4*WDP7,;5B M;6%=W_S2=>F"\73-\!3!*&=:Z]=;5W9R^@;`U#*NU^MU>[66\/7.=K?;=/`&9/'-)7S_2JM9=_$&%#(:3Y?0VJ']?DH]ATPXVRV% M;P!\HYK"%RB(ACRZ-(L)C]6J6(OP?2[Z`-!`AA6-D9HG9()]B.(NCD:"8LT` M;Q)__/QY.1`R:"'1 MBR^?_/;LR8NO/OW]N\*1R5D1SBB!4-?A.KL$S(P5SX15Q/ M*O!T0!A'O3&1LFS-;0'Z%IQ^`T.]*G7['IM'+E(H.BVC>1-S7D3N\&DWQ%%2 MAAW0."QB/Y!3"%&,]KDJ@^]Q-T/T._@!QRO=?9<2Q]VG%X([-'!$6@2(GIF) M$E]>)]R)W\&<33`Q509*NE.I(QK_7=EF%.JVY?"N;+>];=C$RI)G]T2Q7H7[ M#Y;H'3R+]PEDQ?(6]:Y"OZO0WEM?H5?E\L77Y44IABJM&Q+;:YO..UK9>$\H M8P,U9^2F-+VWA`UHW(=!O-29#`P<7""P68,$5Q]1%0Y"G$#? M7O,TD4"FI`.)$B[AO&B&2VEK//3^RIXV&_H<8BN'Q&J/C^WPNA[.CALY&2-5 M8,ZT&:-U3>"LS-:OI$1!M]=A5M-"G9E;S8AFBJ+#+5=9F]B(K5"MQ:FNP;<#N+DXKLZBO89=Y[$R]E$;SP$E`[F8XL+B8GB]%1 MVVLUUAH>\G'2]B9P5(;'*`&O2]U,8A;`?9.OA`W[4Y/99/G"FZU,,3<):G#[ M8>V^I+!3!Q(AU0Z6H0T-,Y6&`(LU)RO_6@/,>E$*E%2CLTFQO@'!\*])`79T M74LF$^*KHK,+(]IV]C4MI7RFB!B$XR,T8C-Q@,'].E1!GS&5<.-A*H)^@>LY M;6TSY1;G-.F*EV(&9\F_W4`BA;JI)6@8,[F3\N>]I!HT"W>04\\VI9/G> M:W/@G^Y\;#*#4FX=-@U-9O]2!=(.SB"QLD.VF#2I*QIT]9)6RW;K"^XT\WYGC"VENPL M_CZGL?/FS&7GY.)%&CNUL&-K.[;2U.#9DRD*0Y/L(&,<8[Z4%3]F\=%]6QEW:"?K?>^[P,3/6:U31FAA9 M\37GGON8.T_RYOOG*#0^^VD6)/'([%RV3<./O60>Q,N1^=.#[3%9^C#N+ M)(W<'*?ILI6M4M^=9U0H"EM6NWW5BMP@-@N$Z\A3`8G<]&F]NO"2:.7FP2P( M@_R%89E&Y%U_6,9)ZLY"4'WNV*Y78;.3#?@H\-(D2Q;Y)>!:R6(1>/XFRV%K MV`+2^"9>1TZ49X:7K.-\9%KU):.X\V$^,J],HU!YFLQ!XL__62?Y=W\L?MY] M^^Y=^]_??/?/'_WYOW[Y>O/>+]^8K4J,@`D?[,>\;.^%Q>T"N55J,+Y9)#%7 MI#.$FK18^.;[#?CLQOB2H?H>4F8I$8.+T,_=B5V([]X M8NJ&P2P-Z+&%&P7A2W'9H@LL,,KGH@!NHHNM0L)YY(JOVE2`G7F?3K.MTG7ZCFDFQN.DW$MAUFC3E`8'.^_[M MV%1AH\JK`X&2OLM$5QG.S))UCOK^:Q.ZT,98J MKHUO0G^18^26!LM'^LV3%?Z=)7F.V?'QS3QPETGLACAL526JWSTEL7Z`I8*1 MF3\&WA.$27.211^[$/%6$NHXLJG7;??M=M_N65?%P*8AT9$_#];1IG:U[*W^ M@QG)MH<5%VP8UT+*D2^?(FF1%TKW*99@KF:>5BR`F*A"0K%$$SKRZ4)5'842 M:CH*!11U%$JHZHBJLZUR59:<)VLL7;UVL.,,VNUB:D95SGY`@?B6B-E.0BBS M:<^#1;98]&"98W5%?MFH&Q.+_E@O'X:?*)?_8U$W'YBY&-\\+X3%2JP@TVH>K872 M(:8'R\.BJ2A.P'%7(6MG(<-=K<*7^W4T\U.'+2LS$>PJ34/RLPEKX_CY^S!8 MQI'/YE[,`N:'-,E]+V?+WFPN=A>?[@X^G1)(A<\I\NT=\F$G97N<(A]C^ZU. MA%VTRD=P*[1TI/1[DIF% M?(M`YV;&R1X")XG9U?.UV80(>F"`[<( MTL`^BS07E4+.A4Q.8+]%)@WV0X2@H%2DFP+H:*$@.**CJ?WMB!PTMD)J(35Q`!\MM8+W$SI2BW%&,P@4=&5((1HL72E2Y*`K1W)7 M6+I2I$!!5X84/:$K18H<=.5(P16Z4J1``1;1DB%%3^A*D2('73F2NZ*K*T4* M%'1E2,$3W3=.D2UQVK281!7F3]&'W3T5"@=5P__7OGI>')Q([>P:-`&K*EZ, MGHJ1(WS!QE+"4)I>`7&KN5/C,4F#WS#(I%=!/$RF^JE)KP[E@2=>^9*ZJP?_ M&4/18LGB>7&2@@WF=!(:N<@NHKXE'/.N"SU(?ZO;'8P5@7A M=*@D>V?N5,@-K*%`TR`LM,G+;'5#8M"&?KQ_V/Z3<6&\]R@7HVH65J!W^6;K M(,3>&6HAJ)'WUADV&4R*BV5:WH>%!K'`LJCK+F"A%WTL%A!*+.KX"5APY[%8 M$%]@=:G;P+&P!GDT%CKC)19URP4L5+UC>:%(B27;OJ=H>WN;']D`EO,BE55X MB5C1:PH/*Q6-R/8"A@V1!R+!;W([P@8B'(E8W(]RK'858U7$XGZ48Y54/I87]R-0!7O9N'$L M%O>CG"=LQ3PAZLC]*-N^IVC[UQE5CGA+,>(+%.X['`DVPHM42C8J4+C7Y"CO M*D9Y@<+])<>WK1C?!0KW%/`$C6S<4/%Z@5+[J"M;UU:T[L2=5UE7#AA+T21X M4]U;A_B"0$+?'V"C*;S>+BI$_)F&)S3`TDUP=J1E6`[IY7H1N[ M>9*^"JN%DI_<4X?Z2)+6-9`0+IRJ$_HJO->!#$`;L4EA(CF'J/1\#4]<% MV3RTG'(,#$H7;.3XHXGO8V!0NH"1DRKUGU1@/L2K=>TA.9=2TZT"\3&(G_RY M'#FRA2V05$&Z]]=YZM;Q)U911%C)_= M-*;:(E7=5S&Z0R,^1X3>__R9;Z]C=L_I>R9LXUT]'H!YY_["78?Y0WUS9/+C MO['MR`BF\JD?@L])SB!&)C_^2/N\48NQ&P_IYF.&OY/;BYX]G=S>.L.VU9[^%R:CC[]&PO8)4]RONZ9`?%#2MK4N7"9)H%!3_?77W_=`[__X=LZ$H\J MU6$2?SCHM-H'0L5^$H3QPX>#^_GH^.)`Z$S&@8R26'TX>%;ZX(>/__.[]UIG M`O?&^L/!*LLV?WCW3OLKM9:ZE6Q4C%^62;J6&?Z9/KS3FU3)0*^4RM;1NVZ[ M??9N+$P>AW_+U.?ZHL5 M(;A5:9A0%`)Q);/&S7W$*>!8C2+Y4%_E:"DCW;AGD*Y= M_^CXN-,][G7J*X\IV@P,*7Y1473\-4Z>8C%34@.V@1AKG:OTA_IM1Y.D_E5Y MI9^3*(\SF3[#MFC'[<6U1UK6EATDZXV,&U?:Y?#K.L&&L\3_ZHG92J9*BVF><>["JOHVBX!:K]NX MCH`,7;_VZ*=FHC@$E8.V^^9=>?9)1C+V%>P$(VCQW7TL\R#,5/`]/L^NQ.'W M=1LX,WL=3MMN_-'%6>(K2=BE=4-F"<9L.Y;Z$NMX8?Z-:/Q MGX97>S8U_%L>;@I27"=1T+@=>\S7>02$!2)08&`_E-D.OIRH3"S#;[AJMQG3 M^9?AW1XS)DE\O%$I<3%!?_<"9J^[?W/)?QW*11B%6=ATY"#76;)&+&3P2*C9 MM5$J&EILY/.N2/9MK.W/XAA1-6[9R#1K9%3?/D8LTV3]RJ6^G^9PW#X,3)(, M:;C'+/K1_?::356X1/N=92Y\X8+9?#KX\#">UY%GV01^ M)S8Y;*&2P-)4/,HH5QXJ9-M#=:$_0ANJD7FV2M+P[RKX7RJ@)V>GWEGGDBOV MI7=Q=NF==XIKDRTM>?"OWB@_"Q]5M",2(`4@%IE"J78XBO5E MZ(=[,HZWM$*Z0/(<(2U>N+3D1-['FVZM,]LMB!AB1&4A:MM>=JOZN_!T?9?5 MR[8NMT%X^?*2U_=<3X5+$:=HD2S%%'G-?/$F?NZ]670UV!LB!^G-99.?+O[2 M7Y!`\K._UG_XF`'"H!,F&'KU\V@+T!VGGA0,5P4\?4R``&RKB,HUV\Q6;F/ M):ZGLYD8W4UOQ/1V>->?CZ>3Q@8-"8\G@^G-4'QG-]FHDI\AJ@5D`*I)%AEG M8LNH0T&2BCJ>$RIP=4NO$XWHUU<(U**13^,X4TC>S)%??26S9WZ("$V(O[,> M:-A-<75[(V\T+OC4GXT''-_1_?7UGX^OQM?W+I2,"A-].)N6TFIO?SV1PP&D\^U]>H9L<`HD*, MHN3I3=DQZ,^^B-'U])=JG">?17\P'_\\GH^'LS_4'TAU.4(XZM_W@U]1$4V> M9@D(U$]B'_J49`;?(/`M??;)QERC/A$J3#I3D2:VY4K;>.35"S+A-DT>0VH3 M!:H]5K3J1B0+))/2/MK&!NX=FH)0;Q+-7$XYJ)QXJ6^M3'`B),T>\-.T2A_# M'97_K7AO/&&CVYKNXQMVYE*A`.N/I\B^&ISZ374, MC2<_#V=S`/4E#-WF(#2IU8M>;YA#P=7RD-LA'=&4R6=6R;BVN.]U75=]8-E. M#963'8/YUB(NZ;>ZQ<6#N92^\:8B#AM*--+N_ MO;T>W@PG\_ZUN!K/!N#P^[LATZMC/A@SFM[=<'5K/(2(BILI0RVFL+QV%:N& M3'YK-@23Z>28-UG*$=B_"Z+UA]RI((>?`44@)BY%6`2Y(F*5P)R[!/2QL6P0 MQCK'3*=)@?LIK5RBZ4E%HV`$Q2NM1:4UH&)@& MN6BBIBE$(W2C:$*.?V*[^IC*^*B.%YZXR^GO5KM'P<46($>E M-/>,T+%C69"FS3UX`F,4)XT#%-M0'S;AF4V!.(">TI6@%+R"`]1@*/D`@]O_YK'!KN%:^Q89>>J[!T#/&PW5?!<$60$ MF#P+\&XP<\)XRUH'M(/_2"`Z)_](*4O7/M/<#DH36\>P1JT7Z-C=P,8SA/^T M"B&OZ>*%'0#Q2+CB/Z`(P)'OAL;LS(,F5&L%8>Q$BA^-+(V_L.,&FAC!]I!M4`; MR;!S^P@!JC`.T%52OV%S82'79N*RDG@X9_U:!LR/"``>MZ8\I$"["9>]S_J) M5VT8T6V)SPE1P0""5J5QPY7J6R8^19A)O,)@%K;_^<<_X653/ZLYO#4;!J'= M)B:"&.$9%EEM%P#%P&$$J3`&^P.:$OTC68COR$)/&$C3)6J]H:$2&(@C+J/P M[X9=$'4S^^*$BW#($0+9%GLEI>F0B0A@^(M'Y*D1;HM<`R):M\27Y`E]:>K1 MI3(PPQ%3E)Z2]"L;9N8C=K(!30ZRS3`'KP.**:[8)W$W8A[BR M1%VBQS'96X(NT2^U)MBM<0`[5.?HVW&N$2+Y")T^J(F[#R3.MOVP,Y?=9KD< M7T)X)BG&LS(DWMLN+((D7^`D:(%Q!GNZ'&LS0GPFC[P0M`;N*$5_^S(&'$@S MS%8I;5'E\@T(A=JQ9!WZ^+X8(1!_!FRNSE'ZJ,5>BBWM@%^!'5`"PH#6G?(5 MY7*!`<13@3`0,*H.'D=`19C84UP_F:(I]CNA'M3*50Q`E'B1!33=;/.5NDD@ MS'F2S*YR`5G.<`8\TO29;G5D8`N!^2?ON'EK&>],\NOP8959AC0XH_Q!='T: M"N%AV8JE!M*-&"I[;OW[7__^U\V6LLG$12+30*R9,^%%<*6-O]T9^D^<:\#K M6!L$'Z&`Q`;CUF?81;*AG-2>6`!9<<(9%*-E12)`CZ-]Q=F5H/+PD"H[)=O2 M")".T\_=[(]HXHR'+$$$J3)3DI#0\$H0`*Z13";$40CDE,'M6!1919FJ\R6- M+0EQ=AQ*T=,8"E#E"Y%MA"8Z]G+,4>KYBV(0$YMF3RK"LVSU6281(,<^0PS* M;0_\MD8506@.T>[I&F^@*2K5_I9OD$C0(T[XE",VL30?/=2`S.. M11]*)>+C_4J(2^-R*6*Y(#-HW%'W.(NU/SMD'%'-`;ML@]D.AP4N*`)"6`4L'; MX"C,+8DKMZ,17G=4R=/*3758@S%!"J""[2E,93UB6L='C<((9_XQIW:(SG`K MUMO9'!WS7+8O@;R2B>0G*;XB#Q/B*;@+Z!/$XH>=;H\/C4B^V/X6`YH4VVD\ MN\_@[.48*"F9V\"(('6)5[#>5U9YK/>%&9D):'KK#]`9\#F96N^0% MC,(GYJ2MF2DLM$!U#D]3=+X)!V1G[9.6`#ZVRJS;+?E9$S[9!'-6Q80"$TJ9 MC9V84[CJ'N$CF`DC3#N)(QQV2*?]>\]Y"HP$VLG$8;O5/B5%;YYD]LT>Y(IK M&8L+.;Z@^0>VU##XM!&ZZO"K.G:C\4D$FP(Z3P17LG^Y=X#C:'=6/5"DX*;> M17M;L-[0)S5L`80-AJQSI?@U#QYX)/@$YI5/$`[DUP2T@:3#1V("3=75QTDG M\]@F0"N&+28G!@L4=G`U20D@I'"@+!,HN`D+:16:H MC3&R9:D4)/Z\5)56Z.QE1`W^LZ,<&"B+[AG=`+?^ZIO3E"266K"Z'";D+B4. M!]8=@5-&'N+[BQY0Q^:XL+A<\:A]Y$$&Z@T@(LD]/AVO<4Z>#($7A&N>Q M1.)L.K@K>TH$:(Q.$1?06ZZ^PU)V(R?`Y;EW>7I>1-;F="-X5SEF0I"F<,E; MFN0J]T')XLT./);;F`*%!*PND$5ISX-@O!^$K:(ZVT;:4!9/4%`2Z'":*A;\ M[T;)B.G:5$H@!;:EV)*YJ?(^""7+0JUDA*:?5.Q6;.S`#I!S:6*?\8LA;CY2 M8F?*V&WRN3?82`4=GH!6NUC@?6WVT&>7L\<[)Z=>][0C"/1.`V`P0&\X<)R) MK(75V&XJMQU(OA$"1!*_*6(0CY%.O-]Z6\6;2`^TVIP7!##>;??,NSSOF>W5 MSIXJ5$]L?:."-8Y]D33HJUA(NA)C6ENF";'.,YK.%6->*AD;C,9@"N)"UZ`C MI4X&8S\'"WL)R1Z02<5HRFQZ`](69])@VZ6=G+2656%-CPJ4AI!B%I7$WSA[ MRS#!E%SIZ(102-_3E7;UEC@\]TY/>[P'0CWD,3A&BY%"VO.6 ML0]83X-V5PNL_B&G@P4X!TRZ$3\T8(A*-T,'C\$H[!1#YH8Z5!L7O##B*5T+ MWF[F1-5A>WC@A=QGBCCW\)JJ(>A:EB.89E!"LI?>_&+(=;RSTXN].=_P"4J_ MT:F=4ZY,)XZAF9FM+-E12<@V/.KRC..UE3XL9\YZ/>^RVZG+F5%.30^F1F"D M&S0ZQ2,-'&I*HSA\.NP:E@2^082N+E#$(2^*AH:526-[E-;TN.H>O9>*K!V0 MN.3C-IL+LQ%1G#YE.CRT!7=;T,EUI_:U)))[Z#A):`"^6_TLOF/M!N`:_=,M M"2`RF%S"<7]/:TW MQ1R+!KG.Y_4"3QR+EPB=KX%G>GK#GR-*:5+B#9^RE873BK>P^.MR!W^"][': MW@6:C*H_\$1WMRUC)LMIG)D\0Y*0IZ1Y\XN!WFYURC[#_C7JOZ:)G9UIUJ0] M^RV`E*"1GE4Y?43;>INE+FW:*X)7M;`4L$[70X"-:"Q)-Y(<-`Q'SPJ2-I-U M;5\9('X$,-8[AC,E>4$K5$;PW+?9(GOB"1MTVQ0`&\Y$>D/.V&-;(O@#G(P# M"^P(RDKB)(18#VZN6@F#Z9"=AIQ&C!E8X7;2*ZXPXI\3S./X+`!-&"PA:6\G MOR#GCNES"G/,RWCEIF6_/5AIZS1CA%W-&5$GZ>D6SY>6M2A'''ZL![I>M]MM MME7<%L+XHF\KMS=X8K57,D,_UX+0.(7!=W)RXIVTV\X]=0CA&E9B#0C3S([) MQ%8#<7%^XEUT=R2#91N(XP[VT8.+7FU57ZM'E13=BB_N4<$_>()1QO_?:LQY MJ1RC[>.W:OSDXMSK]"#'20U6P_`H<>J3\V`23.`XC]H6OIA6;LI'U$M<_%;- MV."ZTQ80Q6?"Z,%VO-0!N*'G,$1+EE0N%E<8]>)H@D8R^X^Y`>0;?M7OE$8; M:('*+BH$@Z2T0@JC])GMX@LSA=XV;30TI![%QPP#!&<9D-"+_$[HG26*+RU? M;FS/X'#\,9W7MK)B,_0*-!V_`-E.7E1+QLXY,>;L.!"EV3!)4KPKC>D1N<9, MBQ=PEQF/K!->F0@'LGB-A)414$*M+2S>8$B=57U!"_#`%FP+RVPSQH_#00\/ M%S&IL/_E`QQ'R_"O+9RODRRUA^D%1P1HIVS#O<'Y%F8*2Z-.1&E(R9/8PD!* M?')@$8P&8A!.[,B<"9'`P5'_?Q=6+A0XQ;:UCT?"NZ/K@VGI#3)R.?D28@/G M!F0%W&XD4K%*$P`G[4OO%&3[WP``QT)T/F#.&:/P*_ZYPCNMY"4ZDC-PHS!( M-./X.U6(.N`'NPAI=JP.HD2F,^L[3#/><*:(U-%H3@(<[%)[L^5W7^9TG(=O MW=:JT&3\%>,*/\&LE_JRPQX:#-+2Y"IW_K/G6+(1VAYU3[N'QGC32:%_0KV? MX"2*CW/VOF"]=XW&$O6:]](PR\U,>)15O_$S-:-,MXH[-;CM"7E)<(+S'9EA?3#EM2:M.-TD/?X?_Q??P_`0```/__`P!02P,$%``&``@` M```A`"N(\W9Q`@``,`8``!@```!X;"]W;W)KV@?;?[]B&M(&N M@XL0QZ]?/^<<'T_OGV2-]EP;H9H<)U&,$6^8*D2SR?&OGZN;$4;&TJ:@M6IX MCI^YP?>SCQ^F!Z6WIN+<(G!H3(XK:]L)(8957%(3J98W,%,J+:F%H=X0TVI. M"[](UF00QQF15#0X.$ST-1ZJ+`7C2\5VDC4PO\IA*M.;E)=HV=I'J[ M:V^8DBU8K$4M[+,WQ4BRR>.F49JN:XC[*1E2=O+V@PM[*9A61I4V`CL20"]C M'I,Q`:?9M!`0@4L[TKS,\4,R6:28S*8^/[\%/YA7[\A4ZO!9B^*K:#@D&\KD M"K!6:NNDCX7[!(O)Q>J5+\!WC0I>TEUM?ZC#%RXVE85JIQ"0BVM2/"^Y89!0 ML(D&'H.I&@#@B:1P)P,20I_\_T$4MLKQ;1J-TG28C>[`9LV-70GGB1';&:OD MGZ!*'%7G,CBZW`+^<7X0#49IDF:PZW]<2$#R$2ZII;.I5@<$IP;V-"UU9S"9 M@//;(0&%TSXXL5\"L`;*L)]E\93L(77L*)E?2@9]Q>(-Q;B3$,#JV"#BZ]F< M&!*+4<>6#CM;CS\/DN%K25^Q>$_10X-]KD=SXAR#=X>6)?V-YT$R]CE-/MW< M]J<7_YSN04%DUT,Y\1G46:7F09(%J/CX.R-[7]/#@T-Z/9X3G^&=)64>)">\ M899FR6:.F&?Z-Z(QJ#:EY"M>+(-:@. M+1\&5K6^!=;*0J?ZUPIN9@[]$4<@+I6RIX&[5+J[?O87``#__P,`4$L#!!0` M!@`(````(0!OZ?:S/04``/<5```8````>&PO=V]R:W-H965T&ULE%A=;Z,X%'U?:?\#XKT!F^\HR6B@ZNY(.])JM3OS3`E)4`..@#;MO]]K MKA/P) M0M-HVK3:ID=1Y6OS(V_,+YO??UN=1?W2'/*\-2!"U:S-0]N>EI;59(>\3)N% M..45C.Q$7:8M?*WW5G.J\W3;/50>+6[;OE6F165BA&4])8;8[8HL?Q39:YE7 M+0:I\V/:`O_F4)R:2[0RFQ*N3.N7U]-#)LH3A'@NCD7[T04UC3);?MM7HDZ? MC[#N=^:FV25V]V44OBRR6C1BURX@G(5$QVN.K,B"2)O5MH`5R+0;=;Y;FU_9 M,G&8:6U678)^%/FY&7PVFH,X_U$7V[^**H=L0YUD!9Z%>)'0;UOY+WC8&CW] MU%7@[]K8YKOT]=C^(\Y_YL7^T$*Y/5B17-AR^_&8-QED%,(LN"((!."W M41:R-2`CZ7OW]UQLV\/:=/R%%]@.`[CQG#?M4R%#FD;VVK2B_(F@;D77(%P% M<8"]&N<+'GK,\W\=Q4)&W0(?TS;=K&IQ-J!K8,[FE,H>9$N(?'M%L!2)_2K! MW2-`MH$RO&UXN++>('.9@L0W(#HBN8&(KA`+:%VYP8JG#HBN8?0J,$\TZE)\-J$V#TUID\<(R3L0>0J/&P%>FYZQ#DZ2-Q%1&7)O8/Y%#&UZ%4,-!/ZS3FB?Q*,^:6/6*@SK* M$(/S/KBTZ?5AC_6/Z[RDV$YN,8;2/.1%)XX5!GF%49\/+*0V[`XVADYKEK0S M%&?X?>T?EVJ[PMSKL;L0G9[4W>E90Y76LD:%GB%&*0:GKIE\/JX3FZ7V\O1$ M),,E]8H51FD&<]B8VM`1Y#&HWT`ZMUFZSU"UM9KV:J2VP$79^[I3W5!A;I== MIS?+`]C8!%PR=ZPPF#K.;)?(7J(!X!0ZB*!3F^4#;&P$+C4"A5'4;`]LDSB! MAG!=T+U^1^GD9ID!0R'7]@))2ZPPJ"`C7AA`]:/MA#U`H\5G^4"'UGW`[=L8 MNTUA<&:7.]SM-16U34-P.X`7Q&M6=7*SW("/W8!.'2L,DO-#/XA&Y##*!1$X M3M\4.CDI\I/%C4NTGCFO7[7*'&+4U)'/>3^URMP0X7$&1X]/,C?+&#@:`P2_ M&H/7M[$BAQ@D=^OXJ((@@'O#\Z6>MUFFP,>FX%%34!@UL^USGQ/VB09A$>/1 MH#5T>K.L0;[,TK)2:U"8N_2&WG"?WBQWX&-W&!PE5&%_[0XJS`1WX,0=Y.6# M#Q)S_U6]>XIL#NH2"H-9!)/P1WMC^+(0A7[41]`+/,LE^-@E/#)SK#"JP"P, MP`?ZR=7.Q3@7C,]=_MG;#)_E%!V:Y*X7!57BH1D\<"=T7)?NHD0%0H8`\H+( M'ZB`ED-GEFMT:$*1NH;"J-D9;$\WHIN88$+/]P<8G2!Q#MF'\O'[?0C7&PO=V]R:W-H965T&ULE)==;Z,X%(;O5]K_@'P_`9.O-@H9%:K.C+0KK7;GX]H!)T$%S&*G:?_] MG(,)L4W3TILDP,M['A_[V"?KS\]EX3WQ1N:BB@B=!,3C52JRO-I'Y,?WAT\W MQ).*51DK1,4C\L(E^;SY\X_U232/\L"Y\L"ADA$Y*%6O?%^F!UXR.1$UK^#) M3C0E4W#9['U9-YQE[4MEX8=!L/!+EE=$.ZR:,1YBM\M3?B_28\DKI4T:7C`% M_/*0U_+L5J9C[$K6/![K3ZDH:[#8YD6N7EI3XI7IZMN^$@W;%C#N9SICZ=F[ MO1C8EWG:""EV:@)VO@8=COG6O_7!:;/.Q.E+DV=_Y16';,,\*;;]CQ<\53R#F2,>SLA6B$=\]1O<"B"(;`48 M1/Y_#G,78A2_#V/^/H=\:*?MG\;+^(X="_6O.'WE^?Z@(-(Q9T^69.D1DNIC,E\&4@MS;!W(P'03&"X'PA6:QOF'%#)^Y0,>T5%@AD83P(BF%)&..=]:Z: M3"MFAF)N*Y*W%!89F(PG0W%$8-3]3"SLN+%6F&1+6Y$,%1=VBPQ*83P9BFVR M&SMNK!4FV:VM2(:**V2+CY"AV":C[@+7$A.-NBM\*+G"!H4T/FLH=MB<)1YK MR;PMS!F=S]SIU,]-]BM@>&*.WA10[(!=*DO7@):8@:E3)LE0960IUZC#O-VWS:Q]1CR?WMI-OM`M6ZHU9FPZR-]0 M45SC0_&:?*-7(?XEKT.0[>2J=:8>;PP MM`65=))%NPU!BQPLZ?(R'7:]?.C'R$SE82MXYV'8=.K6,/C>,TQW`9@LZ?;GUU(U?R9L\37A322\416UD*J>_O M]KUYUS3W#Z#+K=F>_\V:?5Y)K^`[>#68+"$[C>Z3]842==LF;H6"_K;]>8`_ M01S:KF`"XIT0ZGR!35W_MVKS&P``__\#`%!+`P04``8`"````"$`Q7RBRR@" M``";^6(DBC'BBNE:J+;$/[XO'V8864=537NM>(D/W.*7ZN.'8J?- MVG:<.P0$94O<.3?DA%C6<4EMI`>NX$VCC:0.CJ8E=C".JC?=F*P)YID]^`D->O-\,"T'`"Q$KUPAQ&* MD63Y6ZNTH:L>?.^31\I.[/%P@Y>"&6UUXR+`D5#HK>=G\DR`5!6U``>^[5]Y?5APRZ"A@(G2S).8[J$`N"(I_&9` M0^A^O.]$[;H23Z91]A1/$I"C%;=N*3P2([:Q3LM?090<40&2'B%P/T*2-$IG M69)-_T\AH:+1X((Z6A5&[Q`L#>2T`_4KF.1`]LXFT)^_.P-+/N;5!XVAH+8P MC6V59$E!MM!"=M3,;S7I64$@^;D"R'I=P;\S>S%4B-$E\R0[<\?JYD'S>*6Y M*/[(#)C[,WMQB8%]R9Q='(7,03,;.Y(^P7_T7%G(&Q8L]'^@+?]*32N413UO M@!I'3[`-)JQ7.#@]C'U>:0=K,3YV\!7@,(0X`G&CM3L=_`*?ORO5;P```/__ M`P!02P,$%``&``@````A`/!,`6^1`@``L08``!D```!X;"]W;W)K&ULG%5=;YLP%'V?M/]@^;TX)"1M44B5K.I6:9.F:1_/CC%@ M!6-D.TW[[W'+\3GWW&M?EC>/NB8/TCIEFHS&T802V0B3JZ;, MZ(_O=Q=7E#C/FYS7II$9?9*.WJS>OUL>C-VY2DI/@*%Q&:V\;U/&G*BDYBXR MK6S@2V&LYAZ6MF2NM9+GW29=L^EDLF":JX8&AM2>PV&*0@EY:\1>R\8'$BMK M[B%_5ZG6/;-I<0Z=YG:W;R^$T2U0;%6M_%-'2HD6Z7W9&,NW-?A^C!,NGKF[ MQ0F]5L(:9PH?`1T+B9YZOF;7#)A6RUR!`RP[L;+(Z#I.-U>4K99=?7XJ>7"# M=^(J<_AH5?Y9-1**#6W"!FR-V2'T/L<0;&8GN^^Z!GRU))<%W]?^FSE\DJJL M/'1[#H;05YH_W4HGH*!`$TWGR"1,#0G`DVB%)P,*PA\S.@5AE?LJH[-%-+^< MS&*`DZUT_DXA)25B[[S1OP(H[I(*7%UJM]SSU=*:`X%V`]JU'`]/G`+QZ[E` M$HA=(SBCEY2`C(/Z/:SB9+9D#V!:'#&;@('G"Z9',!#ME4'M?&4$HS)6!5/9 MA,!09OJZS&PL@T6?0>O>-HJ;`#&PO=V]R:W-H965T&ULG)G;CIM($(;O5]IW0-R/H9N#832>*!!E=Z5=:;7:PS6#L8UBC`5,)GG[ MK:;:T%78#,Y-,G;_%%]7==VZ*;-M?5!T=Z;JA4V7ER<8(C\V2&/5N5^;% MISI_K8I3AT&:XIAUP-\>RG-[B5;E2\)56?/E]?R0U]490KR4Q[+[W@>UK2I_ M_&U_JIOLY0CS_B;\++_$[C],PE=EWM1MO>M6$,Y!T.F<8R=V(-+ST[:$&:BT M6TVQV]@?Q6/JQ;;S_-0GZ-^R>&N-OZWV4+_]TI3;W\M3`=F&.JD*O-3U%R7] M;:N^@HN=R=6?^PK\V5C;8I>]'KN_ZK=?BW)_Z*#<`QQ^_U3T>:040BS MDH&*E-='`(!_K:I42P,RDGWK_W\KM]UA8WOA*EB[G@"Y]5*TW>=2A;2M_+7M MZNH_%`D="H-('<0#>CTN5S(*1!"^'\5!HGZ"G[(N>WYJZC<+5@W;"8YHG4 M1:`S`")_"(^,*/$-24`5Z9R"($(0$W$>38DW-LQ_R$W$;IR@).IK^B`#/W)Y MV8C"]R)?CJ4G:+#43;1EV5,7L>R-Q<'LH00PAEFP2:1S"H(84L3Y["DQR]Z: MEBU!B=]G3P1\X9FC?AP-UQ(DV%1FUN:1E)@AC6$Q6RA!)'>X93^6XEC8XZY# M-QZ&"9%R-:-ES!,I,2,:PR(12I#(\_GR,D='7@(4WP.DQ!0H'L,B$$HP#4)Z MKLL$*1&$(@Q&`0$3T!R6IZI74[0U7U!:H]G0IE:Q](^L43K5C`VY9FQ#8Q,TN&[/MEFC-7*.8E5!, MU9$-S/E=(+!_FSGT)GBHN>0PBB?+3D?!VOIR#$#)5$->3H;MFY"-_1OW@T"- M)EL'`1.D6C"_Z%C[?R=AV+)-K)C=-5%/8+"5-9;:IN,VQ'Y&%,(/_#$$3=E= M?5],&W_,MF&B-9B14+#]DNIAC2Y\WQ_;-"6[J_V+:?_WF1V"UP:Y#Q ML==0JKM\04Y]P7@.U+5%S6TJ<_P6%?.$A27%O@_QAR?KF"WZ1*)FMJ1S$IH\ MYA$+,:=>(;@5).H5&>K/+4H7UG02&9A&0OF83RSDF_J%X&]1B401[F`)_'P& M*5$(U_?#6\5FGK&0V$PAV="IN.%NGE*.-0CF7$0A.%<",1C>V44C([F7_P\Z9O&\)E M7I9HD4Y0[!MOJAH.HVA!(%UOG""%N\M$O*F)"/ZBDV@1WOL:&P;!\5`$QMJ@ M:*JO+_8W#UT`8@^]&HK"5IT675]U>O#"'8Z=GF*I;FY@+5QTZ`&FE0A>M<2; M,PI=V#D)Y61>\LZRN^(A@BWYQ)OSD!N#E(GYQSM,5WR#OTDD'HINE/3Z(&7Z M(;?PL,V3>HKQ/4$W$11!R88U.6Y#7<\Y">7\(;_PKOB%X'ZA13=R2,S$#VYU MN1_R"CBTX$^E0G"OT"+\#59&'G^L5DOZLQ"PL]]P[?#>)=77>7#^H`8#@B M>_X?``#__P,`4$L#!!0`!@`(````(0">;J-OLP(``%\'```8````>&PO=V]R M:W-H965T&ULE%7;;IPP$'VOU'^P_!Z\L'>T;+1IE#92(U55 M+\]>8\`*8&1[L\G?=P83`MDHV;YP&8[/F3-C#YO+QZHD#])8I>N$AL&$$ED+ MG:HZ3^CO7S<7*TJLXW7*2UW+A#Y)2R^WGS]MCMK#4YLXV1/&T7526+)I,%J[BJJ6>(S3D<.LN4D-=:'"I9 M.T]B9,D=Y&\+U=AGMDJ<0U=Q8"H&,^T5//:[9FP+3=I`H<8-F)D5E"=V%\M:9LNVGK M\T?)HQT\$UOHXU>CTN^JEE!L:!,V8*_U/4)O4PS!8G:R^J9MP`]#4IGQ0^E^ MZN,WJ?+"0;?G8`A]Q>G3M;0""@HT031')J%+2`"NI%*X,Z`@_+&]'U7JBH1& MRV`UG\\6JR70[*5U-PHY*1$'ZW3UUZ/"CLNS1!T+W#N6Z2*8+R?3$$0_(&$^ MH];@-7=\NS'Z2@*1M.&[!,`;BMQV!%<3N$)S0)260JX4N/&S#<+YA#U`Z MT6&N/`:N+Y@>P4"T5P:U\Y41C,I86TSER@>&,M';,M/_D4%P0N'ZDGRXZ'F] MLL?,!IB7$HP,`N1\@PB&'@P-G=;6@\Z0AOTPE&[WZ_K#]N*J-H>^RET$#LR@ M(,N^(".[B['F^SL)P6.I+N(/XG"?P'9[[64Z"R"S]Q5PV5BABXS-K-XV@X/[ M[&.!X+%4%SDULQ[S8F/.,8/+Q@I=9&QF_-?.5]9_@/G6\%S><9.KVI)29D`Y"7">&3\A_8O3#60. M\TD[&&SM8P$_,@F'>()=S+1VSR\@S/I?X_8?````__\#`%!+`P04``8`"``` M`"$`]+-'"J<"``"0!@``&0```'AL+W=OX>Y?H^'*@K!^*UB6\D;ZTTTKZD%?E.)UAS<)'N/G:3Z M<=M>,25;L-B(6MB7SA0CR>;W9:,TW=00]W.44';P[@87]E(PK8PJ;`!VQ(-> MQCPC,P).RT4N(`*7=J1YD>&;:+Y.,5DNNOS\%GQG3IZ1J=3NBQ;Y-]%P2#:4 MR15@H]2CD][G;@HVDXO==UT!OFN4\X)N:_M#[;YR4586JIU"0"ZN>?YRRPV# MA()-$'<83-4``+]("GJ`OPEEJZ7&BU0W!HX)VFI>X(1G-P M/D3F.?I8_Q4JX#F3&^>2X0E&$(6!\CPMHV2R($^04[;7K%[1#!7K@\*5`O!Z M1HC\E/'UK!]0G-BAN-0YMI6?`.^>+3Y[[Z5B/.XE`Q+(T"F)R]8(3M/;1&X3 MZ$X`HF3:^WM(KTE.-.E0L7Y+,6`$DX\SNDT9AD3T28J2V9!@Y3537]YP-`V' MZ^O3]3B9C([K`SXX\1_G&PO=V]R:W-H965T M&ULG%;;CILP$'VOU']`?M^`(7>%K+)=;5NIE:JJEV<'3+`6 M,+*=S>[?=VP#@81L2%^B,!R?XS-C#[.Z?\TSYX4*R7@1(CSRD$.+B,>LV(7H M]Z^GNSERI")%3#)>T!"]48GNUQ\_K`YQ)"RBCSS:Y[10ED30 MC"C8OTQ9*6NV/!I"EQ/QO"_O(IZ70+%E&5-OAA0Y>;3\NBNX(-L,?+_B,8EJ M;O-P1I^S2'#)$S4".M=N]-SSPEVXP+1>Q0PN6^@.FHPCQ8#/P>,0W"!=%&&=2&*VNP M5M99T5MYL(&VC-\O$W1E=-(#*-W[1O4BP+5-^-.&W^[`8L8MS#$5':,`&6Y4 M@Z$6;6/G.;:@`=)P+MK2VOQL,;IXYNHZZV5F$TVZJP@D[EA6?]9DI.-WVA5] M/],:W)6J(O8NM0\,G+M3,\'XNAF]K*M01;IFYOUF=/,=?#\TN"M51<[-++J\ MIA=X5R^@7M45J")=+XM^+QA0P\T8=%>L#IW;T0>V36VNV8#BF'4G(IH*0AU+ M@7?!TDU=!%==P[1$>XOK4(^EGLZ!KY<(V[X`QIK+4X>ZCO`%1S>U"]STBZ-: M%>IQ])_M0'^D3HY='>I:NM""\4T=P:!/CL3%GH![F@*>S/4']$J+-RM/9/H: M0Q!WB38CR\;7!^TT M/EYN["CC-F]@E"C)CGXG8L<*Z60T`4YO-(-,"3N,V`?%2T@+#!12SB4*J=%6W2ILT3?MX=L`$JX"1[33MO]^]&`A.2$M>(-P4#]P9`2GHK?^_&EU MD.I9)YP;`@RY#FAB3+'T/!TF/&-Z(`N>PS^Q5!DS\*EVGBX49U$Y*$N]T7`X M\S(FXSGAM+HGC*#,Q?)Z+0-5L6]J'+F'K>%S>AS`J@ MV(I4F+>2E)(L7#[MGU-OO2H3]%?P@V[])CJ1AZ]*1-]%SB';L$ZX`ELI MGQ'Z%&$(!GMGHQ_+%?BI2,1CMD_-+WGXQL4N,;#<4W"$QI;1VP/7(604:`:C M*3*%,H4)P)-D`DL#,L)>R_=!1"8)Z&@^F,Z'8Q_@9,NU>11(24FXUT9F_RS( MKZ@LR:@B@7=%,I[U)?'LA$I_#\RP]4K)`X&B`4E=,"Q!?PG$W8;`"6(W"`[H MG!*8JX95>%G[X\G*>X',A17FWF+@><0T"`]$&V50ZZ^,8%3&U.)4[FV@+3/J MEAE?(X/@@,+S./GQM.&URA8S:6&.",<@0/H;1#"L0=O0>6XMJ(V\+!+M25>37/!.Z%',[$(?:16$I3?X"RU]PTU_\!``#__P,` M4$L#!!0`!@`(````(0#HA&>ML0(``&('```8````>&PO=V]R:W-H965T&ULE%5=;YLP%'V?M/]@^;TX$-(D**1*5W6KM$G3M(]GQQBPBC&R MG:;]][O&A$+3=NR%C\OQ.??<>VTV5X^R0@]<&Z'J%(?!#"->,Y6)NDCQKY^W M%RN,C*5U1BM5\Q0_<8.OMA\_;(Y*WYN2IOC\T%TS)!BCVHA+VJ27%2++DKJB5IOL*?#^&,64G[O;EC%X* MII51N0V`COA$SSVOR9H`TW:3"7#@RHXTSU.\"Y/K-2;;35N?WX(?S>`9F5(= M/VN1?14UAV)#FUP#]DK=.^A=YD*PF)RMOFT;\%VCC.?T4-D?ZOB%BZ*TT.T% M&'*^DNSIAAL&!06:(%HX)J8J2`"N2`HW&5`0^MC>CR*S)3RM@SA:+% M&WLK'"=&[&"LDG\Z5,?E6:*.!>X=R_PR6"QG\PDDQ&?4&KRAEFXW6AT1#`U( MFH:Z$0P3('[=$5AQV)T#IWB)$>1JH`L/VS":;<@#E(YUF&N/@>LSID<0$.V5 M06VZL@,[95=;E\JU#PQEHM=EYO\CX\`IANMS\E'8\WIECXD'F$6/&!D$R'2# M#@P]&!HZKZT'39"&H1I*M_,:Q<&;(WMJL%O79M'7N8O`EAF4Y(U27XY5WY\E M!QY+=1&_%8>3`@-WYB:&X/L";M58H(N,O2W61E?K&H@`+4R`0`` M0`(``!$`"`%D;V-08W&W!)@VYT6[_WJSKZD2?A+R$<^Z74@M1:ADEW0-S/Q+)@-1J1/J/T/0` MK2@T8,%%I*Q@]-L;(5C\W=\LY$9.27>1LDLZ2,5Y..;MZK>C1-.K].T;,?>N!D\&,&(*BY.X)*HODP1U"6N%`PY;CA3.KQ7Q MUJ\25Q1&P\SIS1HL)>/A\'T".P*;0WY6'PCCEO%R2_]+FCL=].'#XKEFP:GX M6->5T8JXRO2KT=ZA*RBZV6FH1-(-"E:7@=YX0\_I4"3=KS+G,S,H:G@MVA%QX95'I8-.3YA^*O)#9 MYA'AQX83RYMMJ+:7]EU(2IR; MT[X8^X3+>N%FW+']*)T>BJSDAN=LLGW\>"#N>(I\%4BFI>(2\SWFST`8_(?V M=TM'%X/A^9!GNG,FDN,_EOX"``#__P,`4$L!`BT`%``&``@````A`!@1O,^. M`0``:PH``!,``````````````````````%M#;VYT96YT7U1Y<&5S72YX;6Q0 M2P$"+0`4``8`"````"$`M54P(_4```!,`@``"P````````````````#'`P`` M7W)E;',O+G)E;'-02P$"+0`4``8`"````"$`'JC.8$H!``#2"```&@`````` M``````````#M!@``>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"+0`4 M``8`"````"$`>&S`ES4"``#Y!```#P````````````````!W"0``>&PO=V]R M:V)O;VLN>&UL4$L!`BT`%``&``@````A`$U:XXLS!0``*!,``!@````````` M````````V0L``'AL+W=O&UL4$L!`BT`%``&``@````A`')H$.Q>"0``XD8```T````````` M````````!Q@``'AL+W-T>6QE&PO&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`&_I]K,] M!0``]Q4``!@`````````````````[C@``'AL+W=O0@``>&PO=V]R:W-H965T&UL4$L!`BT`%``& M``@````A`,CI@W]:!@``9QL``!@`````````````````A4<``'AL+W=O&PO M=V]R:W-H965T&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`.B$ M9ZVQ`@``8@<``!@`````````````````M%H``'AL+W=O&UL4$L% 3!@`````5`!4`A04``&EC```````` ` end XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 R9.htm IDEA: XBRL DOCUMENT

4. Subsequent Events	9 Months Ended
Sep. 30, 2013
Subsequent Events [Abstract]
4. Subsequent Events	Subsequent to September 30, 2013, the Company received cash advances from one executive officer of $27,200 and another officer incurred expenses of $1,658 on behalf of the Company. On April 15, 2014 a note for $30,000 including interest of $1,696 was converted into 633,921 common shares. Further, on May 15, 2014 the same shareholder provided $20,000 at no interest as an unsecured loan. Also on April 15, 2014, Applied Nanoscience, Inc. and the Company agreed to settle the outstanding $601,041 judgment for 500,000 restricted common shares (valued at $0.025 per share on the date of the settlement) and $175,000 payable in three instalments ending on October 15, 2014. The Company has paid $20,000 to date. Finally, on April 15, 2014 the Company authorized the issuance of 4,610,810 common shares to Company officers and employees at a value of $0.15 per share in satisfaction of accrued payroll and director fees. And on the same date, 500,000 common shares valued at $12,500 were awarded to two individuals for services performed. During the two months ended June 30, 2014, 75,000 shares of common stock were issued in a private placement to two individual investors for $15,000 in cash. Also, in November 2014, an additional 125,000 common shares were issued in a private placement to an individual for $25,000 in cash. On October 9, 2014 the Company issued 2,222,000 common shares to an affiliate shareholder in settlement of his unsecured loan of $444,400. Also, on the same date officers and employees agreed to receive 874,820 common shares to settle $131,223 in accrued payroll. Subsequent to September 30, 2013 the Company generated $25,025 in gains from expiry of certain accounts payable under applicable statutes of limitations. Also, the Company generated gains of $487,137 from settlement of various notes payable and from the expiry of certain notes under applicable statutes of limitations.

4. Subsequent Events

9 Months Ended

Sep. 30, 2013

Subsequent Events [Abstract]

4. Subsequent Events

Subsequent to September 30, 2013, the Company received cash advances from one executive officer of $27,200 and another officer incurred expenses of $1,658 on behalf of the Company.

Subsequent to September 30, 2013 the Company generated $25,025 in gains from expiry of certain accounts payable under applicable statutes of limitations. Also, the Company generated gains of $487,137 from settlement of various notes payable and from the expiry of certain notes under applicable statutes of limitations.

EXCEL 15 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\S8SDT.3@S-E\V9C`P7S0W,31?.&1D-E]C83-C M9#'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I% M>&-E;%=O#I% M>&-E;%=O#I.86UE/E-T871E;65N='-?;V9?3W!E M#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-T871E;65N='-?;V9?0V%S:%]&;&]W#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/C%?0F%S:7-?;V9?4')E M#I%>&-E M;%=O#I%>&-E;%=O#I7;W)K#I%>&-E;%=O M#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I!8W1I=F53:&5E=#XP/"]X.D%C=&EV95-H965T/@T*("`\ M>#I0#I%>&-E;%=O7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2!#96YT3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)S`P,#$P M.#@R,3,\'0^4V5P(#,P+`T*"0DR,#$S/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)U$S/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M3PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'!E;G-E6%B M;&4\+W1D/@T*("`@("`@("`\=&0@8VQA6%B;&4@+2!R96QA=&5D('!A'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\S8SDT.3@S-E\V9C`P7S0W,31?.&1D-E]C83-C9#'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'!E;G-E'0^)SQS<&%N/CPO'!E;G-E*3PO=&0^#0H@("`@("`@(#QT9"!C M;&%S3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S8SDT.3@S M-E\V9C`P7S0W,31?.&1D-E]C83-C9#'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'!E M;G-E'0^)SQS<&%N/CPO6UE;G0@;V8@861V86YC97,@9G)O;2!R96QA=&5D('!A6%B;&4\+W1D/@T*("`@ M("`@("`\=&0@8VQA2!F:6YA;F-I;F<@86-T:79I=&EE'0^)SQS<&%N/CPO&5S/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA65A2!I;B!T:&4@;W!I;FEO;B!O M9B!M86YA9V5M96YT(&9O6QE M/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE M/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0@0FQO8VL@6T%B'0^)SQS<&%N/CPO'0^)SQP('-T>6QE/3-$)V9O;G0Z M(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE2!H87,@:6YC=7)R960-"FYE9V%T:79E(&-A6QE/3-$ M)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O M;6%N+"!4:6UE2!A9&IU2XF(S$V,#LF(S$V,#M-86YA9V5M96YT#0IA;F0@ M8F]A'!E8W1E9"!S86QE7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQP('-T>6QE/3-$)V9O;G0Z M(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE2!A=71H;W)I>F5D M(&$@;F%M92!C:&%N9V4@9G)O;2!.86YO#0I-87-K+"!);F,N('1O($Y-22!( M96%L=&@L($EN8RX@=&\@8F5T=&5R(')E9FQE8W0@=&AE(&YA='5R92!O9B!I M=',@<')O9'5C=',N)B,Q-C`[)B,Q-C`[3VX@2G5N92`U+"`R,#$S('1H92!# M;VUP86YY(&-O;7!L971E9"!A#0HQ(&9O7)O;&PN/"]P/@T*#0H\<"!S M='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E6UE;G1S(&]F(&%D=F%N M8V5S(&9R;VT@82!R96QA=&5D('!A6QE/3-$)V9O;G0Z(#AP="]N;W)M M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE2!I M;B!T:&4@86UO=6YT(&]F("0V,#$L,#0Q+"!I;F-L=61I;F<@:6YT97)E2!R969L96-T960@82!B86QA;F-E(&]W M960@:6X@97AC97-S(&]F('1H:7,N($EN(%-E<'1E;6)E'!I6UE;G0@=&5R;7,@86YD(&%N;W1H97(@ M;V9F:6-E6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@ M3F5W(%)O;6%N+"!4:6UEF5D M(&$@9V%I;B!O9B`D,C8L.32X@4VEN8V4@=&AE($-O;7!A;GD@:&%D(&UA M:6YT86EN960@:71S(&EN2!W87,@9&5S:6=N871E9"!A('!E'0O:F%V87-C3X-"B`@("`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`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2!D96-I9&5D('1O('!U6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE2`X+"`R,#$R+"!T:&4@0V]M<&%N>2!R96-E:79E9"!A(&-O;7!L86EN=`T* M9G)O;2!A(&-E65E('-E96MI;F<@8V]L;&5C M=&EO;B!O9B!H:7,@8VAA65E+B!4:&4@0V]M<&%N>2!H87,@86QR96%D>2!R96-O9VYI>F5D("0S M-RPU,#`@87,@82!L:6%B:6QI='D@870@4V5P=&5M8F5R#0HS,"P@,C`Q,RX\ M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="\Q,34E(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S M8SDT.3@S-E\V9C`P7S0W,31?.&1D-E]C83-C9#'0O:'1M;#L@8VAA'0^)SQS<&%N M/CPO2!W'0^)SQS<&%N/CPO7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\>&UL('AM;&YS M.F\],T0B=7)N.G-C:&5M87,M;6EC&UL/@T*+2TM+2TM/5].97AT4&%R=%\S8SDT.3@S-E\V9C`P7S0W 8,31?.&1D-E]C83-C9# XML 16 R8.htm IDEA: XBRL DOCUMENT

3. Significant Transactions	9 Months Ended
Sep. 30, 2013
Supplemental Cash Flow Elements [Abstract]
3. Significant Transactions	In April 2013 the Company authorized a name change from Nano Mask, Inc. to NMI Health, Inc. to better reflect the nature of its products. On June 5, 2013 the Company completed a 1 for 10 reverse split of its common shares. Following the reverse split, the Company maintained 9,869,710 common shares outstanding. In July, 2013 the Company issued 465,909 common shares to a key officer for his $123,000 in accrued payroll. As of August 1, 2013, a Company affiliate converted a note of $25,000, plus interest of $3,396, into 130,000 common shares. The shares were issued at a fair value of $39,000 resulting in a loss on settlement of debt of $10,604. On September 22, 2013 the same shareholder loaned the Company $30,000, plus interest, at an annual rate of 10%, convertible at $0.05 per share. The note is unsecured and is due on September 22, 2015. Repayments of advances from a related party were made in the amount of $10,380 for the nine months ended September 30, 2013. In August, 2013 a judgment was awarded to Applied Nanoscience, Inc. against the Company in the amount of $601,041, including interest at prime rate, plus 2%, and attorney fees. The Company had already reflected a balance owed in excess of this. In September 2013, a note payable for $13,832, plus related interest, expired under applicable statutes of limitation. These two events both generated gains of $97,957 for the Company. During the nine months ended September 30, 2013, the Company received cash advances of $210,000 from one executive officer with no specific repayment terms and another officer paid expenses on behalf of the Company in the amount of $6,049. The total balance outstanding at September 30, 2013 is $423,249. A gain of $145,251 was generated from expiry of certain accounts payable under applicable statutes of limitations during the nine months ended September 30, 2013. Also, during the nine months ended September 30, 2013 the Company realized a gain of $26,973 from disposition of common shares in Medmarc Insurance Company which was a mutual insurance company that was bought by another company. Since the Company had maintained its insurance through Medmarc, the Company was designated a percentage of the final sales proceeds from the sale of Medmarc. $7,553 was withheld as Federal income taxes and is reflected as other receivable.

3. Significant Transactions

9 Months Ended

Sep. 30, 2013

Supplemental Cash Flow Elements [Abstract]

3. Significant Transactions

In July, 2013 the Company issued 465,909 common shares to a key officer for his $123,000 in accrued payroll.

Repayments of advances from a related party were made in the amount of $10,380 for the nine months ended September 30, 2013.

XML 17 R2.htm IDEA: XBRL DOCUMENT

Balance Sheets (Unaudited) (USD $)	Sep. 30, 2013	Dec. 31, 2012
CURRENT ASSETS
Cash	$ 0	$ 9,409
Accounts receivable	28,900	0
Other receivable	7,553	0
Prepaid expenses	30,000	0
Inventory, net	41,554	42,165
Total current assets	108,007	51,574
FIXED ASSETS
Equipment and molds	933	973
Accumulated depreciation	(40)	(519)
Net fixed assets	893	454
OTHER ASSETS
Non-performing assets	4,230	4,230
Total assets	113,130	56,258
Current Liabilities
Customer advances	21,047	12,545
Accounts payable	205,300	449,331
Acounts payable - related party	0	10,380
Advances from related party	423,249	207,200
Accrued expenses	686,799	687,336
Notes payable	696,226	521,157
Note payable - related party	30,000	25,000
Total current liabilities	2,062,621	1,912,949
Total liabilities	2,062,621	1,912,949
STOCKHOLDERS' DEFICIT
Common stock, $.001 par value, 100,000,000 shares authorized; 10,465,619 and 9,869,710 shares outstanding, respectively	10,466	98,695
Additional paid-in capital	21,874,495	21,624,265
Accumulated deficit	(23,834,452)	(23,579,651)
Total stockholders' deficit	(1,949,491)	(1,856,691)
Total liabilities and stockholders' deficit	$ 113,130	$ 56,258

XML 18 R6.htm IDEA: XBRL DOCUMENT

1. Basis of Presentation

9 Months Ended

Sep. 30, 2013

Accounting Policies [Abstract]

1. Basis of Presentation

The results of operations for the nine months ended September 30, 2013 are not necessarily indicative of the results to be expected for the full year.

Certain minor reclassifications in prior period amounts have been made to conform to the current period presentation.

ZIP 19 0001354488-14-006148-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001354488-14-006148-xbrl.zip M4$L#!!0````(`"4PC$4^G-I=C!L``""L```1`!P`;F%N;2TR,#$S,#DS,"YX M;6Q55`D``_;*BE3VRHI4=7@+``$$)0X```0Y`0``W%WK=]LVEO^^Y^S_@/&D MW=US))M//9RF<]PXZ7C;V*F=FR\>%"E1%O5PTKII M4UD$<'^XN&\`]'=_>YPEY)YEDHOTS8E[ZIP0ED8BYNGDSY6.Q6MR36?LG/S(4I;17&2OR3]I4L`W MO_SK*LWANRCG]PR^U63.27#JCDBWVV+,.U%D$2L'O+ZX_D"]XCNL3U_G% M/WT<`[U+FL-3^#+XQKMT/?S+_>1YYYY[[O9;4LII7LB2DO,X M1UG"S_%O`BQ+Y?FCY&].IGD^/S\[>WAX.'WP3T4V.?.@V]F_/OQ\%TW9C'9Y M*G.:1NS$]DIX^KFIGSL<#L_44]MTK242MS3\,WP\HG(Y,@)\HOT:$G@:YV6' M:N/P3#^L->6-37NZ*;=-8[;23K+H="+NS^#!&:Y:UW&[OFN;9VR\$7+O#)[: MAER*P'/[3\U/M[`="MF=4#HO.XRI'*G&YD$#&'B2B83)QC[J24.G5*1I,6O& M%>?96;Z8LS-HU(56+.-1V6][IWH'P(!?-Z-33QK0H<*4'=(9GS*:Y-/32,Q4 M8U2E$ZL<*%#G4HGM+1L3)8OG4[5"*4UG7=OA]%'&)^8QTGUS(OELGH!@G=FA MM+)$`K3_,2<\?G/R/A,S"\]Q_.5CLOR9TUTC/4YL![$:^C`"7*&I9OY?"%OQG]:WFH3E34V.7?'9?%I]WMXS/RF>C M].Z?7>G=YU3ZTC+^&06P9AF?T7TL8YG^RXIE=K>,7R*6"5#@W3\;;RO":"9P M/&$L4JXY](^[RS6VS!B51<:^-_G0.;2Q@]E'=1(XVH;Q[Z8T8W(C"2,IJM'> M-`#?QPUT8GX/Z['.6^Q[C=D15ALJCW?GP2K&IE$K1"]9*F8\W49V.U]6Z38- M;)_7N-#$4$BMS]\IX;QE$R[S#*0+BQK$",\MIG!/)6#7'Z[(WU5FV"%7:73Z MW=FF(==)O@6UR&ARE<;L\2>V:$VSJGH;1ZN2NQ01+$Z:?X*4LS45U^G^HL>O M=F\:]J/2OG?:@+4>OVH"-XY6)7Y=&U@\=1HZP+P*TN2GU+QD-Z!A(N4Q5=2%F![6PN?J`K`AM'6 MR?Y3)$4*/FKQGBZ3+@GM>;!UHDJ,&^!VQ.1 MM=>HNQE-H!\IAR=OQ6Q.TT450FWH)CU8KOA[^*;]3/%S70=61MI,3"O+;N1^ M:216&;+SXF8,HNTOC=[P6?8\]KEM>HKE10"%I:]0"=+8E9 MQ('/\LT)@!@,`44;`H>"L96*I\`$8;`?F(L(6%@D(!/Q)9MG,";-N4CA<\+P M`W2_F*%$_5M]OW'H?;D8.$O?89G%"=_C\D]S8\,=,2+GO\@S]-D*N M2!P.J`TOA_V]`5U(R7)IS/"^#(&PQ7'ZE>6L#KHSQ7;2$_:#E@2OTGOX%HS[ M`78M<,.J,:D.N2NY5I;+I9+#>-_F494=95A\W^ZJ" MM972D<"U8=%AP,#@"`ASY"V+&+^GHX0!:P]DES<8.G7#O9'$H7!V9-!.4!3; M]K8$KN_ZSJIBMJ?12O=[7CC81J(B`GOKO%>=267`'6FU4_B6M'[F=,03GG,F M0=#O%L)W8<>*V8Y?EA M?]@+W4/@7<0QQU@34BCP+5?I6SKG.4WV=@[NH!\$PXI3WT#@`!QM>`.!A1=X MO=UQ0.8\$ZF2.G4@:/]8,>CUEM17A]V';*L0>="K,G\;V8J=V7O%G9[7\]Q& MV[4CN383=(>N!_9I5W*'QCQ/3')#@-&.^*%3WD#\6N1,?J0+C(%NF=+_CS13 M'1(J)6YSQ,>-FG>@>&2PK2RYVH@S?) M"A8?3ZUZ@UY_6*^/-!,X"$D;;O0&?=_O[8'DLF"?Q(H,'<:4BIQN'OPP&*VL MCN,/]H)BL[#C*(GGA'Y3NKE54EMB:)6U!$/?=W?%\+:0N9A!@A/?X^G;@UT0 M1!05==TP^@$@6@F%%P;A[B"640B(SDV&NQ\L5@')1Y:I+>#67+$[QA5<5]?O M3[X_=1RW,>[91/%((!NY]B5`:A(713X5&?\WB]MQ<`,P==Z][M"?('4@JG66 M?1E4-T6.YR_PAL.!S`IZ8:]:UW^*U*&P6G,+0_^^^Q2OGD!E39JM*BY+:/+P MBF$_#/UUZ_DDJ:/AV[.$V`H"5L&R MT_=0YUHA*(6-RND1(AX'I. MG)-O)_GK3U-&QCP%B>+0E:=C'`-1P^MD$R[%^!`CLK_P/,IF:BK:$FR(#2*V%QU+ED`W8`,GX,R M$Z`,-',`.=N`"(CJ,<$.$#RZEQ41/I`*2B[(>VA*\)R1:GH!,7&4,#+HD-L" M_W_J^$2,R2V;8`$.1[SK_G1*<$4R-,')HH-#RRI')(8`N(DI22Q(*G++%P)S MJJ)3&#+V>\&1"Z/%;A.G:5H`M2:ZI^23PE1!(J>B2(`((QFC,:!`KO]6I%$) MI&237;#&&2&74LPRL6G&@(/EHL.8V-T<6_DO:1%FZD0+`=Y99O^$^+'M@M&, ML!1Z*PB78*AG(Y81W^W@?4"O0\8@T^1ARB.-;403M&0P'<;R^DI+7*A\2G,2 MX[DID+T8!..>Q98;ZY)2F1?J$>6:$[A,-/X-XF+]+`584M)L8:\_J9":&%L+,&!N`>OUJD)0]2GC("@4T^E7K]82"0=UQ\!<9W ME`#X!"-V5"&[!CS!58C!+N*M5+WD2V(@CB#A[''.(B7!AMJX@!5%67LQ''[+ M,A17,N/0&Z8?F9)79/C,T;QR>*2%C-"9BHC(E-XSA459X!D%HP0\`^%'1<*/ MR*[(1&*F[[SBF"H,7#JU0QS8>L45S"'8G\4EEU$B\-#M5W=VQJ*9Q0UZKV6S M#4'FUEV;-B=2%C,TX!7K"$XIT?LB/"T8&B]*)L)D#Q'+`)4V>FK*LSG&;-*( M.DW,T2*4?JJWUP<%Q%R,88"2*O#J5J@AH[BZ,_FQ:QV>T.*\)*D,7 MK"'#$9S3D*=?WL[OS1D3=(`:@,F.V9RI>9!B#D+'H(V8\0B^OV>)F"]C#UP, M643H#.KN%^(-T!*4'`AVF/+&$,^,H/=#J4L0D(`K&2$:-"S@& M)U4+:SQVHFVM+,;:/.>EP88UDB"K&#*@K41-23'G,+:?J)=\:$DJ0S2\R)4_ ML.2^C-3&(@%U,JY,.Q50)!60ZT!L0QZTDC"!-D)N59D?@@;)!%L,THV67:VW M47,(WDQBI/2K,KEQD<9E(F>GM_0A'9VB8"8`XJ947D%5J@*/5ITPRC&,(TYA M`4%UH06D6K+NRF9T`=:%?2[]([I2S>-5(!6?I,`PKI0CGV:BF$P)TV=L@-F) MH/@<-$#R$4R^2"6+T#QU"`9-"3("LA^0)+1M]6&5+DJ6C+N&++"H4:DK3@^Y M1JSA+=//JK'>X/'8&(VJBK+-@@!MBODHK+X2JTS$D%\;2RWP9[S\5%TS$TD8 MHU<*YPS3.21;QNYZX)B!F,2-4>=3D>+:X28T')#0WXQ50;`2FEZ#,X(@Y!.( MAJ2Z-/!5X\VKE%Q`Y)[H[*G19CZ#=,94@[V&59^G`"KM:[3'-BWNHR-@G23DO\M('D+.^L0T8Y`K7`ZWJVFJ@;0:&!+VP,W2&=7:`'&CG3CZ#'12HGB`2N%H8 M(;QR/;^#+T_"1$!OHI,Y762P'"^&;Q?*:ET4$[";Q+5I"UVJ&_`$`BQ]`P_= M@=8[D6LK"GU?>2$R"2QW4DA=U6%22?YA'@;JYD'D@+^OBCEF(78L' M[:74:H%K,C6D>W6$3(TV5`/HN`ZUP=:I5(:$A34((_.D+#C%;*1AN$ZGYP2G M!'1VF0AY7D56)-H1!4,?SU3.B,4U.7JE)[`RSXZ&@+%I6>A#;@%=U_FF8[D& M'HWAI%XYITZ(%05-3<\?N:F+Q,;C*<>!E3N<>0/H\,6(WRT#A=)1+B8"9H-& MVW*JLPFE=+@%I.1#U6IT#J\YKS,#L\S^P&E36UMFP2^%C^@OE0[;>B'YK8@G M2A,>,.=\@,1%1S<7<_`;\!$]I53%"Z9E6/E%.J&X/5`WH&DU!T-.]QRWXP1N MQZ2!6A>-WH.0@^,&=4(U,,KB@2*@2-,<8ML4+.V86=U?%D=,E2C!POS"NF5E M;6RU6SSH\CI[M'DO)G*GX-&K*F(,F%*JN3[5HF3B%7P_\#T#R8I6J<<8BW+G!X14[%<^&_;]8@3PLLAL@-)&\6IQB]D`PMUIW`;#8EAI"92#<;7KT,6Q%*-CL).F M\*U=MMJU@?1&0MB,(2WNMFC#0F!]9SH4!XE7N8?MA#>05*0-=M=$1BF$A5.: MC&U%_0D=``T8:AG.!8;OI916SD`TEM[0LK\*(+3P8("7LOX72M2U'0["CA>Z MRO`L-4$MGM(Q#+2(J;W8C3W-?JNN+=4/'>1.4@<)>")%9T,W!6%3UYHTZ.*S MLDWEK+U>9]CW]31C+B&-Y;9`50\YH?T'%@/W(C!<-AFO:H*NTBFS369%7JB] M7-O0U.=T]HYM1IA&Y[AM:L7;-#DE=USG^34K6TT2,/U8#FU2;*O9^]TNZUY+T8 M2?9[`93?*5?S5?/S)1B,*;;M?-1LNW;SM4BOV:8KK>IW/+#\3=;;;J64%EP; MGTXO')!-=OS%F-L;6Q]Q=0$BL!&/BG1,JM40G8FQ0H)L&O:4WBW3.I6F]7R_ M,_33#C>C'+ M@VX&655?HTYC\*T+4F931P$IJZP_I)"*KD M6+LAE8W72U[ER;48TB3<,#99W`50$>G2$,0J[[-"6$=9$3S7ZT`;G=17TE-, MI?!@"]B/`G?"4*`ER^XY.@N`BP,^DVO[727)H*Y[HJVW`##]>B_LR MP0XZJMQ5[OWH*K>N`ZZL>#M,-*U"4D"\.I"7LN`W2ULX;-!^PRFOXWG>.C>M M743FEW79JN/EJS70::VLB#Y6*7\0!)W`<>SRKJKO1A.B'))%8:(Z,N@'G8'7 M8)",UWKE^B[,QW_)9?1M\7!MD9=)L9)R+[0'DW2U:$NF3';-DNTJ-T.P%2H= M%P:#?L?U^QI#793N:<9%(N%`D(8.N';BR;Y5$'<015:-3@A=?\%1(?6R\GF""CGF1@=DE M8YWD5#?XU2&'$JN-ALOU>3'V"R03SQRI@WZ8WPTZ+254GZ6H22E1,5I6^HTG M!#4"7S%A4A^+B_$5K7Q4Y.I4OZKM@+LJ1UF7Y<`9=D*PH+IVN+L\&Q'6!TH3 M_AE^G`H1*Z.$.XJ*(J*DDNFRTPQ3;%6$`D)X?@1$!'RE/;Z&@FV9H$A"@%2@ M,U2[5J-%_90`+:2^[V"GN)X4+7=#(C%)55+PRN^KP%FQS!Y]JY\_K1T=WT5$ M73?\IK7;:?;`?@97J5S(Q=%8_+'[-E!FX&8_-A>76+]M\ M\BIP`&+DFEMBVTG6$.)5INK%LG>VCG5C8ZA]+TE7;JYM)=+PSM<=[V;:%Y1O MO9L)J)R^VW=J[X3=X7KFKPR/9[+X`L^%3MAU@2)[,U;]*MWP-'T$XG+)DR)? MN7S;:IDW7\0-_7!0N>JV'Z#GFU;3+RO9.JW!('#[O<$?>E9KOQID^ZQZ/F07 MSA]W5DV_/J'-I6LW]/W^L:=EWY1E;]RKYGO9QTV7_KO.J5.Y_MQ(<&]43\O] M%E3>,Z)Z0FZWH`J?"]73GW''53>)K&5Z%%0;I6W]1>&?`6(3PO?ZML)@J'SI3%N%<6U-Q\/J^]J MVAGDC;W@=*5VAG]>?0GSGC+8#0:.WZL(80.=/:'L*FA=-_#\ZFLFC@IE)X'J M!JX_K+Y,ZGA0=I6;;B\<#O=$\LYN$1]!4/JNUZN^1G.-R%XH=I41;P@X!L^` M8B?Q&/0&0?5M?L=!L:MD@&&NA;Y;4=RQ)(''^G?])OBF^GC&4_4;8C"I,MV. M(2RA/Z@9E7:4CX=W9Q_7A]!T\%7Q[B2`8>`.!U\1[\[.SQFZ!\.]99)A&1DS M@>7%T"-*K=OSJOKT)+V#P>TJHLX7!+:3++IN^*6@[6PA#UC0MT)")/:C$+&\ M$\D>A9@&..'`\?QJ@;!&8@\$N\?RX$"=(R/825I\K^<'O6,BV%DH!N'@_WL[ MM]TX82`,/U%5?,)0]2;-*A(7+5&2MM?;A%4C55"15DW>OAC8W8$LA['_S4VJ MJ!'_Q^##>&S/R-4`M^Y,YXT[Y?ZW&)?)\%WVJ>8KT,EQ*.%!P&X&1EMKP`2L M9J"--D(A";C-P*36RM4`6;_#`IQME(X$61".%#P`V*T@LK0:#P2`-Q:(YAL@ M`=A#@4AI>K8%@"]560T77\#6(*4Q\2"_]818$!5_21[%.GD#*M[J7&J=V'-3 M<1N3;18]V@>J^`,.Z4BC$YJE=J#`EN>W&9?N&2G/#-TTGX%Z66'R[)6.HNNR M66T7Y;MLCZ$_/5;EY?Y`>M;F*72>Z46[YR\@PTNB:!!IK302F1UDL73/Q9>X M,_^=NT;CBH8@;!G1&6/P=`]QKE4XXMUL=I;7/CZ:*QOTPM.R[JA`5T$TZ_." M;8KN7\B0^CH)[6FQ,"SV6&=DI(P/E\N$[/ZXO['RZ>7KD^M,5_M\31?'C$`0 MYR:-9308%E>J8[G9H8TH$0-'PYO[>.$_W]$R'>"..243@L,V6IQ*/M%U?VMR MG*0:M=?ZJD+DM%PH&CN8*^A>@B\9NE5),6VQM1\2WK0BK>-`IJR_693OR.DM M<#="\Z>E$4<22D1X.-9/"M? M%S6"!*93I>T@$+*LBV)EMV*I16K.P$KK`4$:L(B4U`N@5!1"R39G*E(LY+BB M$,*6B:$GW98U,93\GJ]L:L&@^XK:H*X>"S''1]2"T?CFTYH&&P/I^EK;FV)7 MN'P))VMN0_KYR+7T(SG?^["=+&VT0KU.>XQ_5(8'8O2N(-&IQW.E/0(2<[++ M(RG8$J-B[FMT4:SL73\Y.SA.@QYNJ.3E[>%V9K[[5I0/50UVAMY)K61DR;68 M!5$$)'NL[(Z\(S@Y*M0[)Q>*QEX?:JN8:.VD=%,\=+76NK!OOWKL2Q#W_W5P M)3.2YP\1APL@.--+L(_&:&,A[W'TMKJE4WNOM]A4_R!SS\#O'`OX(;#O_L11 MRJ%PWI+;C<_+S3%=9;[#K0>5'EWIFE0+1@L8#%>!M>VO^ROJ7N*&O=C5WIQ1 M\03Q7=+-0^Q-=^JVUMZ^["0``G74``!4` M'`!N86YM+3(P,3,P.3,P7V-A;"YX;6Q55`D``_;*BE3VRHI4=7@+``$$)0X` M``0Y`0``[5W=;^,V$G\_X/X'G8L#V@=_9[L;=_<*-TX"`]DXC;-MWQ:T-(Z) M2J27E!S[_OHC94?*JU M&ZV:`\2E'B;/GVI?QO7^^&HXK#D\1,1#/B7PJ49H[=?__/,?COCY^*]ZW;G! MX'L]9T#=^I!,Z2_./0J@Y]P"`89"RGYQ_D!^)([\_M>0A.*8&^(%B*/KL_:< MBT9[XM3K&F..:<1_. MH-V1O]I/G4ZOT^ZUWVN>*41AQ+=G:BT_M%KMEOA9LW_T,?F[)W]-$`='&)'P MWI+C3[59&,Y[S>;+RTOCI=N@[+G9$9S-OS[?C=T9!*B.B32F"[6$2XZ2Q]>^ MO+QLQM\FI'N4RPGSDW-TFXDXVY'%MUA!OR,)QST>BW='713&OE!Z&J>00GZJ M)V1U>:C>[M2[[<:2>[7$^+$%&?7A$::._/OE<;@]*PGP#)`?SAHN#9KRVZ9` M*`J`A'WB79,0ARL)%PMB:84&\7`S!E/AH(@$=>D2TC7D.7_0X0U7<^'<'`=S M7UBD>:B8OR%?VG0\`PAYF5RYQ.<0Y`$QH?X,0NPBOY)4N9PG$E$&&4A<^&@Z MFLML(?`H-9J:ZPRB72$^N_'I2R7)]IA.!BO'8O@'!ER<2,O[%2PG$NJ6BOGB MB@JG8:72Y-&>"C3\3/!4."H)GQ@B7,XT.@ZE9CN5<-&$P[=(('"]D"Y2*E4! M_8G$$0B$`@@QV6,HE267^+R@#2!$V.?WB,D`7\"!(!8-.`EXTBACYUDQ6$Y2&O]TW;J3L*U^Z^H%YWU$$YJC//) MGC^9IH3M"`FW25K\OV%QUCS.CU\(BCP<@O=34J8D@OK430GGRSJ)LC2^&]GB M8FB*^"2NB")>?T9HWI2X-\$/>7(D]H1ZJ[TIC'[8'/[:YUP(M0Y@$3ZX]6*QD(,3<%^'Z5N:%H M\BA8.U==(!A4(\HV;NNRZ-1(YX!!?P M`DU\N(>PW$V47'JP=`S#HJ.Y=7")]G`/A(!+J2%313#.XM9CUP.L: M!J^"':S#<$CDK$S92OA;,5AI*CU4+@RCDJ>9=>9/XCYQFM?XYU527PF['F#O M+,F!6K:P#LD'1L5*/5P]B'HK+BZ_17@NBS!E8*FY;%3GEE'.#U!HPV>^2M(! M:B_!ZQC#.I<4`14%TKC@#6#.P,6Q><3_/L0&)UX_H"S$_XV/%VJIS#\G.H/Y M,NT`OSBU@7,\J&[8A>*\7;9$LR<Y)F@3J\%C.U7JB:BFRN*8QJ"=B3E$IO?E-&&1Z&LU<`\0ESJ/R`6Z^@CSO$4@U<)L-)!S&_6'`2DIG&L M`W@0P1/-"%^&IXI'#[Z?;8"O7/43HK5_95CVMGU-JIT;H<6.**LU!I8&R(Y:6@L(RXKN`M]_0[7!.*3NWS/J"ZMQN=S/#8X-<1ZMR84< M#0)*8J'B-E/%"FZ/TKP7%1L^NW0K4-,Z5^I['I9Z(_\!86](KM`WU'HR[X!+\`$\W#=)%\*GRZ_^=I/%\=J%K$. MT*V:0R*F+KA3-DWE$IOT1N0#?Q310R)0MJ_M$5J4S_<-G_6P?"UMK43U%2L. M,>OZB^XIH6F]2E.=@L6@(K=BG2+/@Z2+20\3N7LT?4++8J3T MN,W71E7AJV(5Z^),"*A3&V7(+,B$>7(7S<`YE):6%SIJE?NG37MG?.*)J"AN*!L#6V!7K(S9E8]PH("WXC#F>T>/#]E##'?^/L6U!XXA M%&6CE5[?"P29"M+G_T.L""A3MRA*5BU.\RVDQ\%3P3SV MY4OB,D`5#.`*3`&^4^LJ1)E>N-IK\9M!/Q(W=^,:R1+)>6F40F;)M!6[[MH M6>8-X)F]G;@*J/N\FLA:O6FC;Z,W`&_F5N1#2J,MJR:XEN_T:%KH;6";N7VY M(KQ[W)H(6[T/5,5.UH%,Z5T^:V]QJ,`-?LPGTJFLJ\KH\``-UBL%]WCO#IW#+//PW,!O/BVW=@:S+S;N2[S[10`_1-(>UUS8/`S+/'%;CMWM' MO;KK4LUE[;7/PW`L,HMU6#["?#,GCJ9ZL5C,8>VU3WT,R\QA7TFP*[%^,*JY MK+VJ>1B0%8+1,)BQSL`P];*+KV(H53SFRYQRC?;;L*HN6RUM\#R5ZBJG/T+U M<\ZEIU)=M;*SJ?-5]3JL5-_KS_)]-IB[/N41`_&AW7!B9MGVFF8_WQW=N:_+ M2HGY/BMFI^'$7,Z6[8PWG)>\.RLEZ8>LI-V&LS.`DQ[AC$(7O5HK)>UE5MH+ M(>V6TTE8SR=F_ENW=F5LM[(ROFLX&;;OCGWA.ZQ2DK9^B MH/M6KI1&'1U_*59EDP7E+_G:3''D?U!+`P04````"``E,(Q%-OHIZK0#``!N M%@``%0`<`&YA;FTM,C`Q,S`Y,S!?9&5F+GAM;%54"0`#]LJ*5/;*BE1U>`L` M`00E#@``!#D!``"]F-MNVS@0AN\+]!VX6A1H+W1TTM9JLD4V20L#:7IP4_26 MEL81L1*9):G8??L=RI%J.K)E9RWKPK:H^6<^3KSQ'7.)9H=@\XNH@:DR,OG!#7W<+G M6)0R@<;A]=GU)Q(,!T$4A`,2!E\'WGR*\2ZHQJLX>/0BN@@C\Q%^CZ(X"N/P MS9:1--6E:B(%\[=!$`9X+.0G.>/_Q.9C0A407$2NXKEBITZF]5WL^[/9S)L- M/"%O_0B5_L]/5^,D@X*ZC)O%3,"I5<9+FRX<#H=^=;4V?60YG\B\CC'P:YS& M,UY-=2-8-C[V%Q>73=D&UTO0BL6JFLF52*BNRJ:3B*RU,&=N;>::(3>,W$'H MS57JU'FJ%EN*'+[!E)COFV^C)BHO6`8TUYF7B,(W5WU,9ED`UV<\O>2:Z5\F ML[*H:'$&E;M,PA1KF?+"-=5CJLC$_',;K?YUA_>!8L5=CBOB/Q7S;YJ;-1UG M`%IU<;4:]P'RA4JSG<@>B?:65L70_1<)"@-M5?T;)'N"^BCPT7(NL&AD)TV;[;Z2QFXY MFV*AO&P3RJ MCRNN#%W(I)R`FS+0EJ3&X?_M\?&8>,D6!PA<4FM6OZ);Y9DX8)8/GI#;V^E M+=8(`9L6#7\_2,A"0U[><%JF3$/ZZE"<[T79;T$M;=XO[M;GYF$IRH4H)>!)ZI!(;;%O> M&VQK9V]1OEFEC#Q2J4@CZZ$.KI\"_3M*NC`(TL.B.VA/^9U[P`6['`5]@AA M&R6II;U1MK\=+".&P2KBL4=69(=._-I6VP(/=R@$\O+!)VF<]KJK;?ON8$TH MVJ98UL_DQ+?^),61_P!02P,$%`````@`)3",15JF7P!M&0``:5$!`!4`'`!N M86YM+3(P,3,P.3,P7VQA8BYX;6Q55`D``_;*BE3VRHI4=7@+``$$)0X```0Y M`0``U5W[<^,VDO[]JNY_P'GO*I,JRX^9;'9GDFQ*8\D>53R25I)GLK5UE:)) MR.:%(A62\MCYZP\`'R*))_4`>U*U68?J!K\&/C:`!M#X\>?G58"><)SX4?C3 MR>79Q0G"H1MY?OCPT\G=O->?7XU&)RA)G=!S@BC$/YV$T^0]^=7=ZC7L^@S'FTB5U<%CCNCS^BB[=O+EY?7+Y!EQ?_?'/VO"3O M&S@I^94\_.Y_7@\N7]-_72Y>OW[W^O+=Y=\,WY0ZZ28IWW3Q_/>+B\L+\D^F M_F/@A[^_H_^Z=Q*,2"6&R;OGQ/_IY#%-U^_.S[]\^7+VY^K`F_$G^U#B@H]NPQQDLQF"".SZG^>8@?2(-[]$5OZ8LNOZULG*E<]M@ISCV(V\8[H:ZJ=T1?/+MQ.D>!E3UK9NP MB%(GV`E\5=,Z[#'>K<:W>O9KFOA_O%M-5S3KL`/Z$;\50..GU,<>M@KH-.R M%`Z.O8KYW;SLLO3(K94;4&<9Q?4:"9UPU:,=$NV8F+VTF_IMCM,TP"L_<^X&?^CCYB%?WN"R!P?_IQ$3AO(F-JO;C`J`3NQHK805P%1H4,@ M'/;NYB?_V.J@:(DJ6C^>;\O?A2VY#0S_TDGNF1&;I/?@..MSRJ)S'*1)\83Q MJG=QF?>E?\D?_T9'*PS=5>`DR60Y3R/W]_ZSGS3L-Y"WP2MCV)166N'.666* ML$DJ)D;YQ`31OZGH_^Y+*`/WT_>>Z+`OF>&`=;JDMWTQ\T,JS4X2 MJW5.IO98%;YJLD2%.LKU$2O@2"R[BE9K'"9L!B%GE$C*&GOD$$NF\"(P6"'% MQ3F6BN"Q6MI)'J=QY&+L*<8P(BE[+2V%N&UI3@1(2\MP<2U-!%$A>:2F'D3N MAGJ3?DBFEJF?OM`X2;QB[.K?)RD-Z(B,,-.S1HPGXUNR1_-02UY]%N&8H8??(H\3&E0KF&U7,P& MI70@*8-D,IT31@.LR8^<$EM9%B/MCA97A*NQ$XS(E/[Y%_PB-8Z3LTL,"!7,= M.`\"NQJ_VV*#$%;!@MJ/(%I?A*C9ZJ4,HD)=M/75)HXI1C]QG>!?V(GESD`N M:HL!.K`%&61R('BA`*$DV M7/S"0-[N<%(#NSZLE`B#()$)PB:31DDQ,740U>S]3E51H8LRY9^[(]6G*-B$ MJ1._7/L!CIOK+@HYNR22P*R3IR$$B#1B9"JRE!J(J73(D-P9SO`ZBE,_?,AV M&,FG7Q)QRW-8)>C&5%8H"X@]2H!2$GU#ETYRC7Q;&,I+ZI!-C,U7I!]]B&)Y M!*0A99<[0HAURM1$`#%%A$L2^6"BJ)#MCA#3S7W@N]=!Y#2#\1(9NV00P*M3 MH2(`B`@\*@D-,D'$)#OL8Z+5*@K9=H+YHT.J8[))V=9=XKOD;E&I9+F_,3"@ MT>LH-``1R0"F++3*-+,](J7B.J73/&AH-,.-,1;(;QG!0Q7PIQ0"RI8E-QQ46JSDX M4PZPPW&RO/9#)W1]\@5$B:_8A-!.M9-]CP;&"+=`*O0ZY]X.8+D=;(4JW1Q9 M*J-"&_V[T-][M^1AR-E/$IPF&AHVA6P23@RP2JVZ!!@2"6%Q8>:[V6PX7J#^ M?#Y'H=I MP"#&-([6.$Y?I@0O._#PQ\9?TW@!X;=F%FZF:K>',C>FWD7I]\J3RH)72 MF'<>I&P[WX,P8]%16UH>3RF*1UZE?!A?D:KKV:&W`N*I)=,/E3RL$:@!TB;/ MR"]HZ3\3ED$:C%9FVYJQIU#2)IL44*LD$HB!Z>'EV+C0VN+#<`9JW%C!KK>N M,V9H&`&1"3)_$84]XF/H07:Z=Q>2TU"RH`L"R-N^@V8W#%\HXQ:06KN2+XST M=&PGWR.99N`XH;U>^J+I-\S5;3*FK5%53IGJ@G$V+0$W*7D[ZK\?W8X6H^$< M]<<#-%],KG[Y,+D=#&?S;]!@>#VZ&BW`<34/#YJSDU/HB(\2X!(&-J0AJ\T'5RL[T03>$N-C^(`8MV.]0EP=!'"4^ZM6:=2<,@SV"#%U$E?Z*O M/XZ3>UJ9O.6>2PV[T7F) MA3NGE"E"01=&Y8%MBAI'*38;_`@E;?)'`;7*'($8&,[(L?$Q1B():[13!=_H M:FG"<7_I8\^<0MH2NJ*6H6DRRFG405+1#+.(HL<:/QTKYF0<$NDZQF066X(5 M/3?N"NL[``-H8:6*'7I+.R.*AB%@J:'D!#@NM%Y4@;*,TF[AY"M8*FF].`)X M,:22M8-=!"B+L')B5D/5$I"U&'5#!@Q;),`$-UK0)"A)E@3EO\\N+B[I``8] M49U3='EQ<7J1_0\E68849Y,^1K'_)_9^(#^??O?]7T^_OWS+MGB^/?W[]V]/ M_W99RD;;;"JG9'R4K#&[HC(`,CSJ>QX[]^X$4\?W1N&5L_:)$Y;-=V725F,( M:LBU"()8%`Q#U?CXH%0AC>C1JIX?(C=3@,&E&4X=/\3>T(E#0O>DMC5TZ;N^ MK+\T4;3),'-#JF33:X'AG3%4]79<)@F#>_S(P'@(T?68S&PL!FLL+\4G'M(G M%?%O8!%'M_MFQTT[L/9+[;)/"A;A#-%J9Y1LD`:8CI4QZ]2))S%+5^2QX>L4 MQRQ#GWZT*]?L:.Z@,T4RG9"I@>E'S;&J)QWE=`,<";.+M'T>63K3*O$.D!1 M;12ZT0J7F?\TT5NIM-U<($K(];0@0E$PM%+CXY.%4&FT3=,(+2'CW`GHA?]V".7PW1K'#KW#(<^3I#VL M*9>W>C!/![MV3$\F#(8Z.H1@#C) M(&+'VG/"2X.]2AV[@74#^/68ND(!#*=,4#895NBP@)2WU8+!LSD.2)D/-S@D M/C6@.3R\E1^R*YKIZJ6:<*;*5H=$K0RJC92,-,%PL15<;KM$IGR*'C)U1DZG M5@`,?G)]O>F8H.,1EM'("E;D709/'&J'M;.]Q)[-*F_E*=2$DIU0A8,GC]E5 M)P-\+V.>@9Y-YAF;466>5@D,\TR1-IE']1`-E^,T#F`8V@(LURT3$9ZD'BD`!AE' M88I)=6F"'IR4W<4;(<3ZHDU-!%I63S$\?JTFDRI&_3`((AT7M!U'`!FMM1JE MP9H,Z&"*YY"LYT-^MA#X*N<6D`$:<9[:N61#QBJ)1/!JQ*D*`".+`)IHX:\8 MN=/Y(Q!6%/NHBTU?[YW$=V5=LUC6ZA!(!;W.8W73MP0\VJ72+WJZ%V23F?@97F;M;26"HO1?\)O<_#T_U/ MPUG_9HC&=Q_?$Z9/KA$A_\?)../\'$WN%O,%^49&XQL8'T#EGE=Z3^-U$'W1 M[:U0JW1T$Z\4O.0&7DX>##$-0"IOW*5*B&F!V]A%+]0CZ*9Q].1[V'O_T^/;B9G4#0A(%W*,CR('%'0QLCR9:E@"'QSM"Y;2+]^0=T?3OY7%_( M&-^@_M5B](DEY7VG8C>7T!R$M'E\ M=EOLUI)%=!COO@JE$;U1-GL9O5@&X6B;6RN]@ MV"@`U631`-SM3>6]I)]C/\6#Z(N,#"+!3BZ&Y8`*KX5H/.5'%Q:1@,OHV29$-3$D^6[(!>/_0^.W'LD#[Y.HKG M.'[R79Q,XJO`\5M MH_O$]C;)DVF:JUDC2PLC2N88Z'3N,G1C["1X@+/_KTQ[\QQK M^D/@Q@58/A?>TK#&47%#[<[INC-DKGM\)/^%DT9(@@T(V3[+"G>!A"=XDXNK M;V;8Q?X33;9M7%LBU6X)*S=&355>#TK7O`-FZ>5&<2EYI$Z:W6TJ)9)8Q%KG M*P%7=K2-WZ$00(&-.WW`-K<=KI6/Y7*F,:9)1@=XB>,8>\71BM#3WS2\:V'= MNJ4V!JL=E4E)@/O7%O#Y\!U3+4\!0CO(P!M;1";E>?XU.MV25@!?S=Y:!@JL9HW8QK;SBMV2S&9(6J>-;6@]-2M$7\E=YC*AY[Y_3ZMAZRE M'HS90L,,LZE"K@2??&+`7\<-J$)K&M?BM:D(3K5S`DJ,T7*PH?=5T%",^2NY MR-!X7Y]\ZYEQ`3!W;$HV^AEJ@SL0U`ZW:(^@=D\2:.K286YRB,W'RH(`4-G` M4`-**TH!,]O9&;IN\_%H_&DX;[/YV!Z[R;`FWZG8=__8^#'^Z+B/?HCCEW[H M#8N-%I(*,U6VR>)V!E69:Z8)[3QX*]1<5(@`>B3C"X"[:LP_QKV_9JAN=C_W M^E6,&.2XM2,&OU#]6D8,UW[HA.X!1@S*@@!0V2:4&&[2:YR0X&LH]+K61TGF)I1&R+HE,`PTQ2I8)LWTT.T MMMB>1:I)QP=NOID1T.T152.K-Z8;U$E=O"OBB4#+^%:5!4DS`4`UNXHX/657 M]7YZ,!WY#*_ST?5D.>O#UA-YR>6B3'@.L?%;O7(6R MK60>XV&5>T!6+:O?E2'SU"I=>3@3YJGD07HZ0\K)^]+D,8K37HKC%0J)UX2U M:E3]N`QZ5;EX5]Y.UZO*9"%[.8/.=2L.GF+F\Z:])UY09\3[S82_BN".'+Q'7G.A5E)!*@6KMP-I@=D@&.KN*E:6!82*N_0.^' M-Z/Q>$QC69-KFL=O-!E`K.$W'=3P,%0.`&JX9/4['`_,*M9BIV=1'." M(A?9*%Q&\8KEF-#EB3/5MIHRKIU)M>QQ9JI@9CKM\'(YY>ZFT]OAQ^%XT;]% M@]'\ZG8ROYL-64K#(LA-'.WU9/:172P"@[%%ONRIX\NR=-9%NDA:7@4GREA. M?P?#(@$HSH.Q$1\]E9"E%,D4H!""YFI:.,]TUJ7@1$/*_D7$'$3^`N)2!!`Y M1+AT_&!9QU.J!(,CA7,&\Z=Q_ZN(?-`Q38J6_972J!?Y"WQK%0:#"VU$"5GSVB@O-``E\&=7H>03):DBTAH7('% M$4)O[C^$_M)W'?*M<58O\'/Z/I#O)]NO2)L4/83Q51+O4QX8FA_`B.:'<'F& M6*G4[U;+A?$)E.@UCE4@9Y.L4IA5!G)"8&@E0\;=9T;D$!,$YRMO_3\VON>G M+]OYH,X7JE5LTL<$?)5)*GDPI#(`V>37ZS-T$]$N^8K660S$!XE"^\/L@?;V M'B/5KI=D9,;HUF.:>F"HUP(LMQ)34=W>[H,*;7!^;^X^DGE_@"=+ELZH,A3( MPV<+,OU/'!88T(X.=RW,*H'W,KA&Z9U*@D/R?>`W:?_F#%4*0%55(#S?W"?X MCPWY!H=/1HY7)F[7V:I!UQVL6!8.W]0`>4=:B*-,'I[K;!BD]8YR^2Y)I?9Q M,F&PM-)YJN^(IVI2"P:?:&S3S^X5(I-R,H2ETW`NBMD`IXX?)&-ZPTCJ/\E@3J2Z9+:+8L]A`B M`<(BP2X]XSI\QNZ&.AP"W'=Q+.24@9(U2AD;4#)*JP*8PA=MGZ]X)%ZJ4 M44RWH^XDRU5_M8EC23*VF@"@#D.,B]N2P:1.42[7526[[F:U8?U1]8I7\G>` M\_7V_BJ*4_]/]GP:TR2VB3!1IWB!:CZAE-4OH/- MJ:MO.47%>\A?]$VG3&1HDJSOB-22&C_&LA0/4GE`%#""*4CS4&V@>ON<(J+: MJ9.5>U=`%=\`)/:G'55C)>>VHL/BI0!5KP(<=S7E5K3K_DN3V+V:"QUD59O4 M<4=5RU+`/4:!1X:`U%>E+\(E%TX*4$4KP''1E8KH-R@31OTTC?W[3G`ZBMC*$JOI2R7U7'58[82&5Z^_SB+:%7XH0`-8,<&W<7 M7IF.?VAP3,%&G6='1NG%R&MP9S4LY\^!+H?LOC5V`&OX@9071O8-+HSLQ,?M=;4BY*:386WK MVJ;ZK*:V&^Y05Q(";SX97/,69*?@NP^%6;O!#TZ#[@!:E+&5+3!/*QE;7]UE M=_-\B[:SV&U972U5'?M",#CMVA(PMY!5[&I*(Y07@,H20"P[6KL["TZ;[@"Z MY;=:%M7]MWJ0+.YPVDX+4;VSD*ET/,2QEM`<3JOM`+KE%U<6U?T7=[",X'#: MSP"D:*O<*.[<3.^#+,M.VMI- MKJ-8=L93UW)MI^E]RE`D).%*`0I`^J6_O@!)R91$@`N*-"!/_<%Q*"RT^SR[ MP.*%P+N?'F>1=X\8QY2\W^OM'^QYB`0TQ&3R?N_3;:=_>WIQL>?QV">A'U&" MWN\1NO?3?__Y#T_\O/M7I^.=8Q2%)]Z`!IT+,J8_>E?^#)UX'Q%!S(\I^]'[ MS8\2\>37WR](+)X%,;Y'XFGVK2?>F_W>R.MT`'7>TH0%:%GA5?_J%^_@^.C@ M\*!WY/4.?CW:?QR+[QOXL?A4/'SS[\-![U#^ZMT='IX<]DYZWP._*?;CA"^_ MZ>#QAX.#WH'XR<3?19C\<2)_C7R./`$BX2>/'+_?F\;Q_*3;?7AXV'\XVJ=L MTCT4DMW??[F\#:9HYG]_4<>[BW` M3Q%D-$(W:.S)?S_=7"R_E1_3!2+,-H<9HY5A4?\T0%U\$\GZ-2$-*?:2BOSBEPFE8I39E99LB#4$ M'@M')?$=\PF7/0W$H?1B32F7C#CZF@@&SNZEBU1JI2C?D#J"@5@0(3I[C"IU M*2W<+FD#%/LXXE<^DP%^CVJ2J*JF)5*-M0;*Z]2=%^+Z4CQ8$4&/,2(A"A<5 M2:VW[67%8UG)0?;3\SK>0JKXIT@8O:P*KUA'KOI"^8@&*_I&,O^@K`HWF?E] MT>G:'_%89IJ+BB)_A**T^B]2%B;:K:-LCFV:$7$4[$_H?3=$N"OUEW^DAG0. M>GD^](UX]"73X09-L/QJ$LLX\[?X[P11'2Q\:,SHSA3*'C5884D17J/#B%)P*0Y@?78B0>?P9/>DX MV"@*)*'G'@L*JVW0L+#C3E1;COYJ"2#HARZ!7F:C3:RO$<-46!#*<;,>]+6B M0/2/7$2_U&H;-/2%-J'4Z#SR)^7PKQ4!PO[&)=A+K;0!]VG"I(GGF(L![?^0 MS[2.KRX-).&M2R14V6ZOX_V,HNAG0A_(+?(Y)2B\X#Q!3-SK'$6)<1\M&42`=W[M'A$JB^EI%K\W:$Z9')!GL]3:+%4A M`23E!_=(T6-@CYO41TY%8SJA3#MP6"L(9.+8/29*+;9'P'4RBG!P'E&_;-2_ MU'JE&'C,YA[Z)>9:;)CH;$;);4R#/VZGPFX^3.)TS5`$J+9YTLI!V7%Q2`T` MQ.:8+TL!LS'0N7BFZ$0TQ:'D.#GT5IIOGQ.9EH,9*12&\N'D8%QA>@D;[[H; MUEV*!^W-B)>OT:Y,@1]Z'6^Y]B?^SD6\3,;[]A/QDQ#'*/Q/K>GOHD^-?3Y* M^4EX9^+[\\RQ4!3SQ9-U#\L??UDJ.!R?8R+TPR(`*,<5L^6Y.$QZZY"I;UZ? M'T7H"L7YH$CC]EHI:Q.*)E1`#'>+(M$9#N,I8L\:=D4 M0I6EN9R]V9TZ5`!97,'$#?Y$?I3,DDAX;#A``F3AK!)B\7>$4JQ)V)_)A8X_ MT^=*T[399$/?8&^&:7N?:!IG\Y[@..L)")I()=SN"^KU`7`/:6T@V4:K49YU M[63_7TCAJ[O[TL)0AEL;=6[1NVNL=Z,S*"@(H@5.1VM#21VF2O3=0KT*<%.L MF]\S88RU$N:=;+4NL3_"D8AP)*>1TC75*8T$V%RVT?%3=5,&KP&\G]C!]LT4 M)S?"KZ!U/MHVXG-#!LJ@B^//:BS,EAO3R4GM82>F-Z]):[P7;=B4Y=7%H9BWEGG#,=<;XE)@ MB.!EB4A.-TS3MEPJ$2A%K:WNU&F\]/:[0=,5C1&X:RDM#*6FM;&4,34:F]TC M9:UEC7S.\1BCT(BLRDJ@)+:VD+<5B4",W"#7I$7D, M$(EP]EI;C-N&O=="6YUYIP9FFHY:&UIM,4^Q*W-+A;)0!EIK6AES$S%;:[0="- M/'N(H/#,9P23"5]9,A_C`&L:.H@LE+;6AF/&M,$1<8/!30--NB8X0ZTE],8, MJ2W>]72C:C&G_F(7?+M_BTLDACQ#T6B4=;NOFI4?O+GRWME1Q7MG*U7\_>[9 M:QL:_#TP:&)@(()DR%*3PS1KOD8L?6,;-%90"UL[F*R!T4,5),YQF+UBWT_B M*67XS^<&5\O=II#M-Q*WX4P%@:-#HE/*10;[D=*0W])( MFQ.L%;2=!U0#O-ZQE%KJ!@TW`CNAPU2,VP[\32D" MH>`&8;R=:ULHEP6"XT9Y^]#'ATAG%X)V#FMKF M$HME&DH3I`5BI#D/688J.@]1,-ZI*D M,'GW3R50`E*C4W3@/(*Z_%;"L/-)$(HAN>Q:,>NON]?FL\S<7>=PL2UJL3PH M[YD,-/UF>7'KK]77[BAUYKO1,WY&>#(5[7K_7M@W05?);(38<)RJ6UA\2C67 M,U,X2F+=ZFG=^JR_55^7X^T`=&TQ;_-.VI6UO+?:M3PI[*72CJSE%;:I+`TS MVDQ4(F6W1Y0*73-ZCP6_'YX^<11>D.5$2%]>FY[M@*N>)ZA1ESN;CI1L;G:J M-1%SHW5N-P=JK2FMC[I93F3U787_)SQ.FS[YFGI`28#3XZ:?%;ZCC45K.]]F M>TVY1D"W";L;CE4\>U#M$*NE;*]&M\H*U1CN$G'+,Y@_,Y'W#.B#AKZRLK;7 MJU^01#54;E"YF,PP7)!@$H!M(W>,`\2$[C7P\TW!O6(WM=?.7#/8Z`+=TMD_FD[F/F^E]MCGIZV8S2^*&N3F ME%X891+%L/JL[Z]I(:Y-D'2U!5^,_K6G6U6(6=^6TP*W);BX2N'Z"<8_.^=J!RG7QL*6K]]I`6D[$U?%ZI*ZP=3VOH#1O2UC=TM>,0 M"I1VWR?@B[]-;$Z`^T=KTW%;^X$,;6;1U07VFM1F(+Q`AB3[`K"Z'R]K<5UB>*UK*X;@OAW#9_,'!- MM`T.7`K4F*>8(_=*^Y/\:+)&^A-M7=:O*&IN:R0`,T=Z$$8#A,+TNI+G)>;" M`4J:SJ-:U/JM1EO0LW%I*0PG]V@MWL4`8W-5POJE1ZV06(:*&]S=H'F>I`S' MQ1N$]&\]ZZ6L7Z+4&(<0='8_;2MZ*MP']%+6;VEJ)8X!/N!(+,/:8;6$]:N< M6HGABG9X1^,7#E43*;0#-T0UYAOFR.WZL"LU%S%,P_7Y++5OZ&2@KS&\]!#< MW!>JD7D-W.M9=N!2JD;YW)JY>>H08JC.XEW@[\NA`S=0-#E84Y5Y0$XL_G M10T2EG0*`\R#B/*$`4Y.W+YF\!N<#K633>'9T@M;-RA,@NSE03G>SH?;^=WP M^4?+7;$71&@FY[=+2):UU:W,^F58C9%$MP?#I<9`3IN=4H$&XT+;[*]8YH?" M["0]6G0F-][UU$$/KP'J!*T-9IIV`F,$E,Q;N`6-8SX<7Q?J7*JWT9"_*>W[Z7"\KBB%7&+)XEDNT,%>]`+ M7]K0^TYP_R'2+M=N5ZOE0XNJV5V+QR8P="%&/U*YF4VT58@I@O/[]>`\W/=2 M*6\A9L^3EY!6QV))4:N7@GY-<(CCIV=D`2&FE[(<0DHN-FX`K3;=A<@HQ/*= M2*JX'VANS_IA/4B.]KU"!=Y*#6Y-1IUE#R`G[H&D;%U* M>KFHS4!=M0(2G"H)JY/?JTI!8DXM8CVL])QL3&U7V.Y"M(@43J:HB`3%!>]B MJ/0.UD/E[;ZW*F;S9KC9#&=GK8CL>T4KHSE%LVHL7[]:J2D@RDSKL1QZM7@N MN;35'#H7@E21B0Y0[..(7\ECNN2]9>7AVS/(3+UO\SJ]9:7USH563!,##=$$ MK*S&N!9']N>]\%[;QF.Q%O:EH6BXQ[;IP\?2B_^0_-8/Z=&6HAT8CL?YU+KN M[+$J06LG.C=`#=1&AYK%M00+UAX>0C+_QAK"5S(:4`23'%PN3LZ0>Z7/'E&0 M2+"$Q^``,54L`>1V)-<'6E,C:/)/Y*^1SY%X\A=02P,$%`````@`)3",1=FW MM9Y,!@``;R@``!$`'`!N86YM+3(P,3,P.3,P+GAS9%54"0`#]LJ*5/;*BE1U M>`L``00E#@``!#D!``#M6NMSXC80_]S.]']0F>G,=3K&&/*X<.$Z24A2.DE( M0G*]]LN-L-=!K2UQDDS@O^_*#S`O\[BDEVF.#XS9EW9_TJ[D%8>_#L.`#$`J M)GBCY)0K)0+<%1[C#XW2?<7I')0JU0K3HTXE9M:>>CC>$VJD8O$G9^J3:=JOIR[:K5>=>K._IHC M::HC-1ZI,GQ;J3@5_*RG?LF4.U8^H#>[C_O#6_;Q`?C;J$WYU66'5G^/W&O] M^-?QWOF?P?$@#'[Q_6!O?W0S8+^=1Y]'?]^?/UQ66]W[TV3(0^7V(*0$9XBK M1JFG=;]NVX^/C^7'6EG(![N*'MH?+R\ZL5PI$:P/`\;_623N'!PTV.%O/"NG3"G1-E"T;U$E&6BD;(> M*.V/97VJNK%LRK#-VK`JCE5S^(RSV+=*\G&(13+U_"/E'DELD9RQ0WO63,YXI,!K\_?QTXCCVGP?OX&K[JF$@/K@6;H[@*LI_G%P-=6`#]EZY6"/\9'M?UV MWQQ0<+ATD2_A%8.^,P/ZQ`@1/IF8^;;N\_">4-4["\3C`N0GK&+@=PN!-U9( M;.8;\,=4,03V.A=35FGF&<6@[YD]$\^V@5"1!/SAE$ELQ6">M_,ZD3X7^*)T M(K#HRA3B*4HQMONSV%;+)%8GJ?[KQ+3#'CB>4%W*]9VD7)G7QTG)7L(L1OKM M+-*U,LE9(GE3KQ3TJ*O@$_-E6G:WX).XU5M,&_7\*9.8<;!^VD\1Z9XF^-!\N&F_5-[TD!-?\\V60\Q<"$UX7/M MVJ)&?'*%<"'C-_C;"].[&M+?Q9 MXP9EG962U[Q*%,U2.3!+Q=G[0F>V,=EG` M3.FXA+`+LA2[BZ>A%4(LP-W(5!8M(U-LS.U<'8L0$]Y=7"N]2*:]GZ1V)C=: M=4^$E/&6AM"(8:QX1,(:%1G1WZ#;O"&V:/PQD M$:PG2].G+*;-8TPDT`J^43]!B-D"/Y,BS"_R+*P"_DK7DUU:9ZQNS^(F=,?SM)2[P4S\M_&]O@#<$_(7*G- M@EM/=/M(/>@^8Z!MW0-Y"RZP@?$O"VJ>_&*GZA:\*.ZHM/TKH>&:CHR?S0CN MQ)C5XOB>V*?,:W%\^T].OTF@6VN_6#S6[&3-UM*-U5Y<636)&/_-#$S%/![] M(9EI@;9]/YW5J91=*?E2,]9LV_D=XG0(;F2F!MUG+DB5W]]7"6Z]GSQ5C(=V M&UL550%``/VRHI4=7@+``$$)0X```0Y M`0``4$L!`AX#%`````@`)3",1;'HT>^["0``G74``!4`&````````0```*2! MUQL``&YA;FTM,C`Q,S`Y,S!?8V%L+GAM;%54!0`#]LJ*5'5X"P`!!"4.```$ M.0$``%!+`0(>`Q0````(`"4PC$4V^BGJM`,``&X6```5`!@```````$```"D M@>$E``!N86YM+3(P,3,P.3,P7V1E9BYX;6Q55`4``_;*BE1U>`L``00E#@`` M!#D!``!02P$"'@,4````"``E,(Q%6J9?`&T9``!I40$`%0`8```````!```` MI('D*0``;F%N;2TR,#$S,#DS,%]L86(N>&UL550%``/VRHI4=7@+``$$)0X` M``0Y`0``4$L!`AX#%`````@`)3",11H':#P``X]T``!4`&````````0`` M`*2!H$,``&YA;FTM,C`Q,S`Y,S!?<')E+GAM;%54!0`#]LJ*5'5X"P`!!"4. M```$.0$``%!+`0(>`Q0````(`"4PC$79M[6>3`8``&\H```1`!@```````$` M``"D@ XML 20 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 21 R7.htm IDEA: XBRL DOCUMENT

2. Going Concern

9 Months Ended

Sep. 30, 2013

Text Block [Abstract]

2. Going Concern

- Definition

Disclosure of accounting policy for reporting when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). Disclose: (a) pertinent conditions and events giving rise to the assessment of substantial doubt about the entity's ability to continue as a going concern for a reasonable period of time, (b) the possible effects of such conditions and events, (c) management's evaluation of the significance of those conditions and events and any mitigating factors, (d) possible discontinuance of operations, (e) management's plans (including relevant prospective financial information), and (f) information about the recoverability or classification of recorded asset amounts or the amounts or classification of liabilities. If management's plans alleviate the substantial doubt about the entity's ability to continue as a going concern, disclosure of the principal conditions and events that initially raised the substantial doubt about the entity's ability to continue as a going concern would be expected to be considered. Disclose whether operations for the current or prior years generated sufficient cash to cover current obligations, whether waivers were obtained from creditors relating to the company's default under the provisions of debt agreements and possible effects of such conditions and events, such as: whether there is a possible need to obtain additional financing (debt or equity) or to liquidate certain holdings to offset future cash flow deficiencies. Disclose appropriate parent company information when parent is dependent upon remittances from subsidiaries to satisfy its obligations.

+ References+ Details

XML 22 R3.htm IDEA: XBRL DOCUMENT

Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
STOCKHOLDERS' DEFICIT
Common stock, par value	$ 0.001	$ 0.001
Common stock, authorized shares	100,000,000	100,000,000
Common stock, outstanding shares	10,465,619	9,869,710

XML 23 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2013	Dec. 10, 2014
Document And Entity Information
Entity Registrant Name	NMI Health, Inc.
Entity Central Index Key	0001088213
Document Type	10-Q
Document Period End Date	Sep. 30, 2013
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	No
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		20,007,170
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2013

XML 24 R4.htm IDEA: XBRL DOCUMENT

Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended
Statements of Operations (Unaudited) (USD $)	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Income Statement [Abstract]
NET SALES	$ 59,772	$ 154,775	$ 232,291	$ 454,513
COSTS AND EXPENSES
Cost of goods sold	18,582	122,970	158,023	326,346
Research and development	16,268	0	16,268	115
Selling, general and administrative	90,918	174,158	538,361	541,988
Total expenses	125,768	297,128	712,652	868,449
LOSS FROM OPERATIONS	(65,996)	(142,353)	(480,361)	(413,936)
OTHER INCOME (EXPENSE)
Gain on settlement of vendor liabilities and other	97,957	125	270,181	7,490
Loss on settlement of debt	(10,604)	0	(10,604)	0
Interest expense	(11,969)	(10,773)	(34,017)	(31,977)
Total other income (expense)	75,384	(10,648)	225,560	(24,487)
NET INCOME (LOSS)	$ 9,388	$ (153,001)	$ (254,801)	$ (438,423)
BASIC AND FULLY-DILUTED INCOME (LOSS) PER SHARE	$ 0	$ (0.02)	$ (0.03)	$ (0.05)
WEIGHTED-AVERAGE NUMBER OF COMMON SHARES OUTSTANDING	10,415,337	8,841,768	10,053,584	8,638,740

XML 25 R12.htm IDEA: XBRL DOCUMENT

4. Subsequent Events (Details Narrative) (USD $)	Sep. 30, 2013
Subsequent Events [Abstract]
Cash advances from executive officers	$ 27,200

XML 26 R11.htm IDEA: XBRL DOCUMENT

3. Significant Transactions (Details Narrative) (USD $)	9 Months Ended
3. Significant Transactions (Details Narrative) (USD $)	Sep. 30, 2013	Sep. 30, 2012
Significant Transactions Details Narrative
Repayments of advances from related party	$ 10,380	$ 24,730
Gain genereated by writing off payables	$ 145,251

XML 27 R5.htm IDEA: XBRL DOCUMENT

Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
Statements of Cash Flows (Unaudited) (USD $)	Sep. 30, 2013	Sep. 30, 2012
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (254,801)	$ (438,423)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	152	498
Provision for inventory obsolescence	0	7,609
Loss on disposition of equipment	341	0
Common stock issued for services	123,000	161,650
Loss on settlement of debt	10,604	0
Gain on settlement of vendor liabilities	(243,207)	(7,490)
Changes in operating assets and liabilities:
Accounts receivable	(28,900)	422
Other receivable	(7,553)	0
Prepaid expenses and other	(30,000)	14,543
Inventory	611	(14,448)
Customer advances	8,502	(137,972)
Accounts payable	(10,324)	29,194
Accrued expenses	193,479	224,195
Net cash used in operating activities	(238,096)	(160,222)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of equipment	(933)	0
Net cash used in investing activities	(933)	0
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common shares	0	25,000
Proceeds from advances of related parties	210,000	104,460
Repayment of advances from related party	(10,380)	(24,730)
Proceeds from issuance of short-term note payable	30,000	5,149
Repayments of short-term note payable	0	(1,692)
Net cash provided by financing activities	229,620	108,187
NET INCREASE (DECREASE) IN CASH	(9,409)	(52,035)
CASH AT BEGINNNING OF PERIOD	9,409	61,504
CASH AT END OF PERIOD	0	9,469
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for interest	0	0
Cash paid for income taxes	0	0
NON-CASH INVESTING AND FINANCING ACTIVITIES
Reduction of note payable due to a reduction in prepaid insurance	0	3,457
Common stock issued for settlement of notes payable and accrued expenses	$ 28,396	$ 8,703

XML 28 R10.htm IDEA: XBRL DOCUMENT

5. Contingencies

9 Months Ended

Sep. 30, 2013

Commitments and Contingencies Disclosure [Abstract]

5. Contingencies

- Definition

The entire disclosure for commitments and contingencies.

+ References+ Details

XML 29 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 9 88 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://nmihealth.com/role/DocumentAndEntityInformation Document and Entity Information true false R2.htm 00000002 - Statement - Balance Sheets (Unaudited) Sheet http://nmihealth.com/role/BalanceSheets Balance Sheets (Unaudited) false false R3.htm 00000003 - Statement - Balance Sheets (Parenthetical) Sheet http://nmihealth.com/role/BalanceSheetsParenthetical Balance Sheets (Parenthetical) false false R4.htm 00000004 - Statement - Statements of Operations (Unaudited) Sheet http://nmihealth.com/role/StatementsOfOperations Statements of Operations (Unaudited) false false R5.htm 00000005 - Statement - Statements of Cash Flows (Unaudited) Sheet http://nmihealth.com/role/StatementsOfCashFlows Statements of Cash Flows (Unaudited) false false R6.htm 00000006 - Disclosure - 1. Basis of Presentation Sheet http://nmihealth.com/role/BasisOfPresentation 1. Basis of Presentation false false R7.htm 00000007 - Disclosure - 2. Going Concern Sheet http://nmihealth.com/role/GoingConcern 2. Going Concern false false R8.htm 00000008 - Disclosure - 3. Significant Transactions Sheet http://nmihealth.com/role/SignificantTransactions 3. Significant Transactions false false R9.htm 00000009 - Disclosure - 4. Subsequent Events Sheet http://nmihealth.com/role/SubsequentEvents 4. Subsequent Events false false R10.htm 00000010 - Disclosure - 5. Contingencies Sheet http://nmihealth.com/role/Contingencies 5. Contingencies false false R11.htm 00000011 - Disclosure - 3. Significant Transactions (Details Narrative) Sheet http://nmihealth.com/role/SignificantTransactionsDetailsNarrative 3. Significant Transactions (Details Narrative) false false R12.htm 00000012 - Disclosure - 4. Subsequent Events (Details Narrative) Sheet http://nmihealth.com/role/SubsequentEventsDetailsNarrative 4. Subsequent Events (Details Narrative) false false All Reports Book All Reports Process Flow-Through: 00000002 - Statement - Balance Sheets (Unaudited) Process Flow-Through: Removing column 'Sep. 30, 2012' Process Flow-Through: Removing column 'Dec. 31, 2011' Process Flow-Through: 00000003 - Statement - Balance Sheets (Parenthetical) Process Flow-Through: 00000004 - Statement - Statements of Operations (Unaudited) Process Flow-Through: 00000005 - Statement - Statements of Cash Flows (Unaudited) nanm-20130930.xml nanm-20130930.xsd nanm-20130930_cal.xml nanm-20130930_def.xml nanm-20130930_lab.xml nanm-20130930_pre.xml true true